Review

The Implication of 5-HT Receptor Family Members in Aggression, Depression and Suicide: Similarity and Difference

Nina K. Popova, Anton S. Tsybko and Vladimir S. Naumenko *

The Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia
* Correspondence: naumenko2002@mail.ru

Abstract: Being different multifactorial forms of psychopathology, aggression, depression and suicidal behavior, which is considered to be violent aggression directed against the self, have principal neurobiological links: preclinical and clinical evidence associates depression, aggression and suicidal behavior with dysregulation in central serotonergic (5-HT) neurotransmission. The implication of different types of 5-HT receptors in the genetic and epigenetic mechanisms of aggression, depression and suicidal incidence has been well recognized. In this review, we consider and compare the orchestra of 5-HT receptors involved in these severe psychopathologies. Specifically, it concentrates on the role of 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3 and 5-HT7 receptors in the mechanisms underlying the predisposition to aggression, depression and suicidal behavior. The review provides converging lines of evidence that: (1) depression-related 5-HT receptors include those receptors with pro-depressive properties (5-HT2A, 5-HT3 and 5-HT7) as well as those providing an antidepressant effect (5-HT1A, 5-HT1B, 5-HT2C subtypes). (2) Aggression-related 5-HT receptors are identical to depression-related 5-HT receptors with the exception of 5-HT7 receptors. Activation of 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C receptors attenuate aggressiveness, whereas agonists of 5-HT3 intensify aggressive behavior.

Keywords: brain serotonin system; serotonin receptors; behavior; aggression; depression; suicide

1. Introduction

Aggression, depression and suicide are the global burden of human society. Each year, almost one million people die of suicide [1,2]. Major Depressive Disorder (MDD) is one of the most frequent psychiatric disorders affecting 5–12% of men and 10–25% of women [3]. Acts of violence and aggression account for 1.43 million deaths worldwide annually [4].

Despite being different multifaceted forms of psychopathology, aggression, depression and suicidal behavior nevertheless have some neurobiological links: (1) suicidal attempts are considered as violent aggression directed against the self [5], and associated with depression [6], violence and impulsive-aggressive behavior [7–9]. Analysis of literature revealed that 23 out of 37 variables that were considered as risk factors for violence are risk factors for suicide as well [10]. In murderers, the incidence of suicide is extraordinarily high, amounting to 30 percent in some European countries [11,12]. (2) Widely accumulated preclinical and clinical evidence associates depression [13–15], aggression [16–18] and suicidal behavior [1,9,19–22] with dysregulation in central serotonergic (5-HT) neurotransmission. Currently, the brain 5-HT system is the main target for antidepressant drugs: almost all clinically effective antidepressants act through 5-HTergic neurons (the only exception—bupropion) [23].

Polyfunctionality of the brain 5-HT is due to impressive variety of 5-HT receptors. Currently, 14 types of 5-HT receptors have been cloned and identified including both metabotropic G-protein-coupled and inotropic (5-HT3) receptors. Distinct types of 5-HT receptors are targets for approximately 40% of approved medicines [24]. Available 5-HT
receptor density data suggest that the antidepressant effect of serotonin-selective reuptake inhibitors (SSRIs) is only observable when inhibitory and excitatory 5-HT receptors are balanced [25].

The crucial and intriguing problem is to define the similarity and the difference in the ensemble of 5-HT receptors regulating the specific and multifactorial kinds of psychopathology, such as aggression, depression and suicidal behavior. The aim of this review is to evaluate the contribution of the members of 5-HT receptor superfamily different by operational (drug-related), transductional (receptor coupling) and structural (primary amino acid sequence) characteristics (5-HT\textsubscript{1A}, 5-HT\textsubscript{1B}, 5-HT\textsubscript{2A}, 5-HT\textsubscript{2B}, 5-HT\textsubscript{2C}, 5-HT\textsubscript{3} and 5-HT\textsubscript{7}) to the regulation of these kinds of behavior.

2. The 5-HT\textsubscript{1A} Receptor

The 5-HT\textsubscript{1A} receptor attracts special attention due to its key role in the autoregulation of the brain 5-HT system functional activity. The net effect of 5-HT\textsubscript{1A} signaling is to reduce neuronal firing rate and protein kinase activation [26]. However, according to its localization, the 5-HT\textsubscript{1A} receptor exerts different effects on the functional states of the 5-HT system. 5-HT\textsubscript{1A} receptors are found on 5-HT cell bodies and dendrites, mainly in the midbrain raphe nucleus region (presynaptically located autoreceptors) and on terminal targets of 5-HT release (postsynaptic 5-HT\textsubscript{1A} receptors). Presynaptic 5-HT\textsubscript{1A} receptors inhibit neuronal spike activity in dorsal raphe nucleus and 5-HT release into the synaptic cleft [27–29]. Negative feedback control of functional activity of 5-HT neurons by presynaptic 5-HT\textsubscript{1A} receptors was considered as a key mechanism in the autoregulation of the brain 5-HT system. Postsynaptic 5-HT\textsubscript{1A} receptors mediate the action of serotonin on neurons and also could regulate 5-HT system functional activity via complex feedback neural networks [30,31]. Thus, the 5-HT\textsubscript{1A} receptors are a powerful regulator of both pre- and postsynaptic 5-HT neurotransmission involved in mechanisms of sleep, stress response, appetite, sexual motivation, aggressive behavior, depression and anxiety.

2.1. The 5-HT\textsubscript{1A} Receptor in Aggressive Behavior

An inhibitory effect of 5-HT\textsubscript{1A} receptor agonists on aggressive and social behavior was shown in different animal models [16,32–37]. Considerable differences in 5-HT\textsubscript{1A} receptors were found between rats selectively bred for high levels of aggressive reaction towards man or for its absence [16,38]. Genetically defined aggressiveness was shown to be associated with decreased expression of 5-HT\textsubscript{1A} receptor mRNA in the midbrain, decreased 5-HT\textsubscript{1A} receptor density in hypothalamus, frontal cortex and amygdala and decreased functional activity of 5-HT\textsubscript{1A} receptors. Notably, the greatest difference between aggressive and tame rats was found in the structures of cortico-limbic circuitry (frontal cortex, amygdala, and hypothalamus) representing neuroanatomical substrates for the origins and expression of impulsive aggressive behavior [4,39–42]. The frontal cortex-amygdala network supports affective control [43] and regulates aggressive impulses originating in the amygdala [42,44,45]. These data suggested an important role of 5-HT\textsubscript{1A} receptors in the suppression of impulsive aggressive behavior, and are consistent with the studies carried out in man. There was a significant negative correlation found between lifetime aggression and binding potential of 5-HT\textsubscript{1A} receptors measured by positron emission tomography (PET) [46] and by the response to 5-HT\textsubscript{1A} receptor agonist, ipsapirone [47].

Positive correlation of reduced 5-HT\textsubscript{1A} receptor binding in the temporal cortex with aggressive behavior in Alzheimer disease was described by Lai and co-authors [48], who suggested that the 5-HT\textsubscript{1A} receptor B\textsubscript{max} represented the best predictor for aggression.

Taken together, the evidence reviewed above suggests that 5-HT\textsubscript{1A} receptors contribute to prefrontal cortex-limbic system circuits and may fulfill a significant role in the expression of impulsive aggression. Hereditary high or low aggressiveness may be defined, at least partly, by the expression and density of 5-HT\textsubscript{1A} receptors in the prefrontal cortex and limbic system.
2.2. The 5-HT\textsubscript{1A} Receptor and Depression

A lot of pharmacological evidence on the role of 5-HT\textsubscript{1A} receptors in the mechanisms underlying depression and depressive-like behavior are available. Antidepressant-like effects similar to those evoked by classic antidepressants from the SSRI family have been produced by agonists at 5-HT\textsubscript{1A} receptors [49–52]. Moreover, the involvement of the 5-HT\textsubscript{1A} receptor in antidepressant action of SSRIs is well established. It is known that SSRI administration blocks 5-HT transporters thus increasing 5-HT levels in the synaptic cleft and inhibiting 5-HT exocytosis via presynaptic 5-HT\textsubscript{1A} receptor-mediated negative feedback. Applied chronically, SSRIs lead to desensitization of presynaptic 5-HT\textsubscript{1A} receptors that weakens the inhibitory effect of these receptors on the 5-HT system, thereby increasing its functional activity and ameliorating depression [26]. It was suggested that the enhancement of 5-HT\textsubscript{1A} receptor-induced signaling intensifies antidepressant-like effects of 5-HT\textsubscript{1A} receptor activation [53]. Reduction of 5-HT\textsubscript{1A} autoreceptors in adults results in elevated release of 5-HT at target areas and enhanced SSRI-mediated behavioral improvement of depression [54–57]. The drugs combining SSRI action and postsynaptic 5-HT\textsubscript{1A} receptor agonists [58] or presynaptic 5-HT\textsubscript{1A} receptor antagonists [59,60] were shown to be effective for amelioration of depressive behavioral traits.

Conditional knockout of the 5-HT\textsubscript{1A} receptor gene transcription repressor Freud-1 in 5-HT neurons resulted in elevated 5-HT\textsubscript{1A} autoreceptor protein and hypothermic response in mice. These changes were accompanied with reduced 5-HT levels and neuronal activity in the dorsal raphe. Such mutant mice demonstrated anxiety- and depressive-like behavior that was resistant to chronic antidepressant (fluoxetine) treatment [61]. The loss of function of presynaptic 5-HT\textsubscript{1A} autoreceptors results in a disruption to the response to SSRIs [62,63]. At the same time, AAV-based Freud-1 knockdown in the hippocampus affecting postsynaptic 5-HT\textsubscript{1A} receptors resulted in an antidepressant-like effect [64]. Another 5-HT\textsubscript{1A} repressor of interest is Deaf1. It was demonstrated that a polymorphism in the human promoter that disrupts Deaf1 binding as well as the modeling of this mutation in mice are in good agreement and in both cases are associated with a depressive phenotype [65].

SiRNA targeting 5-HT\textsubscript{1A} receptor mRNA covalently binded with the SSRI sertraline in order to concentrate it in serotonin axons decreased the 5-HT\textsubscript{1A} autoreceptor expression without affecting the postsynaptic 5-HT\textsubscript{1A} receptor expression in the hippocampus and prefrontal cortex. This led to marked antidepressant-like effects in the forced swim and tail suspension tests [55].

Further evidence for the involvement of 5-HT\textsubscript{1A} receptors in depression came from postmortem studies showing increased levels of 5-HT\textsubscript{1A} autoreceptors in human depression [66]. In brain areas with postsynaptic 5-HT\textsubscript{1A} receptor localization, the hippocampus and frontal cortex, a decrease in 5-HT\textsubscript{1A} receptor gene expression was observed in postmortem studies of major depression [67]. PET imaging studies of patients with bipolar depression and MDD demonstrated decreased 5-HT\textsubscript{1A} receptor density in the dorsolateral prefrontal cortex [68–70]. Later, reduction of 5-HT\textsubscript{1A} receptor density was shown in the mesiotemporal cortex of depressed patients. Smaller reductions were also reported in 5-HT\textsubscript{1A} receptor binding in the hippocampus, raphe nuclei, insular, anterior cingulate cortex and occipital cortex of people with depression [71].

2.3. The 5-HT\textsubscript{1A} Receptor and Suicide

In contrast to numerous animal models of depressive and, especially, aggressive behavior, no convincing animal model of suicide has been produced to date [72]. The data concerning the implication of 5-HT receptors in suicidal behavior were obtained using postmortem brain tissue studies, genetic association of 5-HT receptor polymorphism, and using PET in patients with a history of suicide attempts or suicidal intentions.

Higher 5-HT\textsubscript{1A} binding potential of 5-HT\textsubscript{1A} autoreceptors was shown in raphe nuclei of individuals with depression who attempted suicide [66,73] and in the raphe 5-HT\textsubscript{1A} receptor density of individuals who committed suicide [74,75]. No changes in 5-HT\textsubscript{1A} receptor density in the prefrontal cortex of suicide victims were revealed [74]. At the same
time, reduced somatodendritic and postsynaptic 5-HT$_{1A}$ receptor numbers or affinity [76] and a decrease in activity of cortical 5-HT$_{1A}$ receptor downstream effectors [77] in suicide victims have been reported. However, the fact that the post-mortem samples are largely composed of suicide victims, many of whom suffered from chronic alcoholism, weakens this argument. Recently, the association of suicide in MDD patients with disruption of cortical 5-HT$_{1A}$ receptor functioning [78] was demonstrated.

3. The 5-HT$_{1B}$ Receptor

The 5-HT$_{1B}$ receptor is a G$_i$-protein-coupled adenylate cyclase-inhibiting receptor displaying 43% amino acid sequence homology with the 5-HT$_{1A}$ receptor [28,29,79]. However, 5-HT$_{1A}$ and 5-HT$_{1B}$ receptors have shown different cellular localization and regional brain distribution. The cellular localization of 5-HT$_{1B}$ receptor is mainly presynaptic, with receptors located primarily on axon terminals. Depending on localization, a 5-HT$_{1B}$ receptor may act as a autoreceptor, inhibiting 5-HT release; or as a heteroreceptor, located on non-serotonergic neurons and regulating the release of other transmitters [29,80–82]. A comparison of the roles of 5-HT$_{1A}$ and 5-HT$_{1B}$ Receptors in the regulation of extracellular 5-HT in different brain regions suggested that the 5-HT$_{1A}$ autoreceptor plays a larger role in the striatum innervated by the dorsal raphe nucleus, whereas the role of 5-HT$_{1B}$ receptors is greater in the hippocampus and other brain regions innervated by the median raphe nuclei [83]. A full review of the 5-HT$_{1B}$ receptor is beyond the scope of the present article but has been well covered in the comprehensive review of Tiger and co-authors [82].

3.1. The 5-HT$_{1B}$ Receptor in Aggressive Behavior

Several lines of evidence indicate the essential role of the 5-HT$_{1B}$ receptor in the modulation of aggressive behavior: (1) lacking 5-HT$_{1B}$ receptor knockout mice demonstrate enhanced aggressive behavior and reduced anxiety [84,85]. (2) Alcohol-heightened aggression [86] and socially provoked aggressive behavior [87] are highly sensitive to the inhibitory effect of 5-HT$_{1B}$ agonists. Microinjection of the 5-HT$_{1B}$ agonist, CP-94,253, into the dorsal raphe reduced both aggressive and motor behaviors in mice with alcohol-escalated aggression. However, infusion of the 5-HT$_{1B}$ agonist into the medial prefrontal cortex after alcohol drinking increased aggressive behavior [88,89]. (3) Repeatedly observed aggression increased aggressiveness in rats [90,91]. These changes in aggressive behavior were accompanied by decreased 5-HT$_{1B}$ receptor density in the striatal brain regions and increased 5-HT$_{1B}$ receptor density in the basolateral amygdala suggesting a modulatory role of 5-HT$_{1B}$ receptors in the mechanism of learned aggression. (4) The SNP rs6296 in the 5-HT$_{1B}$ gene was associated with childhood aggressive behavior but not with adulthood anger and hostility [18].

3.2. The 5-HT$_{1B}$ Receptor in Depressive Behavior and Suicide

A review of the literature, albeit fraught with inconsistent results, provides strong evidence in support of the involvement of 5-HT$_{1B}$ receptors in the pathophysiology of depression and in the action of classical antidepressants, SSRIs. Behavioral antidepressant-like effects similar to those induced by SSRIs have been produced by agonists of 5-HT$_{1B}$ receptors [3,52,81,92,93]. Furthermore, 5-HT$_{1B}$ receptor knockout or pharmacological blockade of 5-HT$_{1B}$ receptors abolished the antidepressant effect of SSRIs [92], suggesting significant contribution of the 5-HT$_{1B}$ receptors in the mechanisms of SSRIs action.

Overexpression of encoding 5-HT$_{1B}$ receptor gene in the caudal dorsal raphe nucleus increased swimming in the swimming forced test and reduced conditioned freezing [94]. At the same time, decreased anxiety along with an antidepressant-like effect in the forced swim and sucrose preference test were displayed by mice lacking 5-HT$_{1B}$ autoreceptors [95]. The antidepressant-like effect was produced by the 5-HT$_{1B}$ receptor agonist anpirtoline [92]. Reduced 5-HT$_{1B}$ receptor binding in ventral striatal/ventral pallidal brain regions has been reported in MDD [82,96]. Importantly, the firing of 5-HT neurons in the dorsal raphe nucleus is controlled by both 5-HT$_{1A}$ and 5-HT$_{1B}$ receptors. However, in contrast to the
inhibitory influence of 5-HT₁A receptors, excitatory control of the 5-HT neurons firing through 5-HT₁B autoreceptors was revealed [97].

Attempts to find evidence for the implication of 5-HT₁B receptor genetic polymorphism in the susceptibility to suicide were unsuccessful [98–103], suggesting that 5-HT₁B polymorphism is unlikely to play a major role in the genetic predisposition to suicide attempts. However, in one more recent study, an association was shown between a few 5-HT₁B polymorphisms, MDD, suicide and aggression [104].

4. The 5-HT₂ Receptor Family

Serotonin 2A (5-HT₂A), 5-HT₂B and 5-HT₂C receptors are members of the superfamily of 7-transmembrane-spanning (7-TMS) receptors. These receptors share about 46–50% overall sequence identity and couple preferentially to G₉/₁₁ to increase inositol phosphates and cytosolic Ca²⁺ [105]. The 5-HT₂A receptors are predominantly cortical, and in subcortical structures their expression is considerably lower [106,107]. Cortical 5-HT₂A signaling can initiate a negative feedback mechanism through cortical glutamatergic and GABAergic interneurons that inhibits the firing of 5-HT neurons in the dorsal raphe nuclei [31]. At the membrane level, activation of 5-HT₂A receptors produced membrane depolarization and the closing of potassium channels that increased the excitability of host neuron [108].

One remarkable characteristic of 5-HT₂A and 5-HT₂C receptors is constitutive activity [109] revealed by the presence of receptor signaling in the absence of any ligand [110]. Constitutive activity of 5-HT₂A and 5-HT₂C receptors can impact and significantly change the therapeutic response of these receptors [109].

Widely presented in astrocytes, 5-HT₂B receptors play a key role in astrocyte response to antidepressant treatment. Upon stimulation, 5-HT₂B receptors activate MEKP/EKT and PI3K/AKT signal pathways via EGF receptor transactivation that leads to changes in the expression of multiple genes and affects astrocytic functions including, possibly, gliotransmitter secretion [111]. More intriguingly still, 5-HT₂B receptors are expressed in the 5-HT neurons and, acting as somatodendritic autoreceptors, regulate their excitability together with 5-HT₁A receptors [112]. Stimulation of the 5-HT₂B receptor is associated with an increase in cyclic GMP through the dual activation of constitutive and inducible Nitric Oxide Synthase [113,114].

Initially erroneously identified as 5-HT₁C receptors [115], 5-HT₂C receptors are found widely distributed throughout the brain [105]. The primary transcript of the 5-HT₂C receptor is subjected to multiple RNA editing. Fully edited variants (VSV and VGV) of 5-HT₂C receptors have reduced G-protein coupling and 40-fold decreased serotonergic potency [116]. Within the brain, 5-HT₂C receptors modulate the mesolimbic dopaminergic function exerting a tonic inhibitory influence over dopamine neurotransmission [117,118]. High levels of 5-HT₂C receptors were detected on parvalbumin GABAergic neurons in the prelimbic prefrontal cortex and to a lesser degree on pyramidal glutamatergic neurons [117].

4.1. The 5-HT₂A Receptor

4.1.1. The 5-HT₂A Receptor in Aggressive Behavior

There are some pharmacological data indicating a link between aggressive behavior and 5-HT₂A receptor activity. In animals, 5-HT₂A agonists, such as DOI, reduced aggressive behavior in flies, amphibians, mice and rats [34]. However, accumulated data also revealed a pro-aggressive effect of the 5-HT₂A agonist DOI [119,120], whereas 5-HT₂A antagonists effectively suppressed aggressive behavior [119,121,122].

In humans, a number of atypical antipsychotics, which act as antagonists of 5-HT₂A receptors, had antiaggressive effects in clinical trials reviewed by Comai and co-authors [123]. A number of polymorphisms associated with impulsivity, aggression and violence were reported [124–126].

Some conflicting results were obtained in PET studies. Compared with the low-IA (impulsive aggression) group, cortical 5-HT₂A receptors in the high-IA group were
modestly lowered [127]. No differences between cortical 5-HT$_{2A}$ receptor levels in high- and low-aggressive participants was found [128].

5-HT$_{2A}$ receptor binding was increased in the hippocampus [129] and diminished in cortical areas and basal ganglia [130] of subjects with borderline personality disorder (BPD) characterized by impulsive aggression. In contrast, Rosell and co-authors [131] demonstrated positive association of cortical 5-HT$_{2A}$ receptor binding in physically aggressive BPD subjects. Positive correlation of prefrontal 5-HT$_{2A}$ receptor binding with lifetime history of aggression was found in a postmortem study of suicide victims [132].

### 4.1.2. The 5-HT$_{2A}$ Receptor in Depressive Behavior and Suicide

The 5-HT$_{2A}$ receptor is the primary site of the action of 5-HTergic hallucinogens, such as LSD, psilocybin, mescaline, currently recognized as fast acting antidepressants [133]. Depressive-like behavior was not affected in mice with global knockout of 5-HT$_{2A}$ receptor [134]. However, in response to chronic corticosterone exposure, Htr2a$^{-/-}$ mice displayed a more pronounced anxiodepressive-like phenotype than wild-type mice [135].

Selective 5-HT$_{2A}$ antagonists generate antidepressant-like effects, inhibiting 5-HT reuptake and modulating the release of other neurotransmitters in the prefrontal cortex [52,136,137]. Numerous open-label and placebo-controlled studies have suggested that some antidepressants and atypical antipsychotic drugs known to block 5-HT$_{2A}$ receptors augment the clinical response to SSRIs in treatment-resistant patients [59,136].

Committed suicide depressive patients show increased expression of 5-HT$_{2A}$ receptors in the prefrontal cortex and both lower expression and reduced 5-HT$_{2A}$ receptor binding affinity in the hippocampus compared with matched controls [138]. In fact, results of studies on 5-HT$_{2A}$ binding have been equivocal depending on the character of suicide, brain region and diagnosis, as reviewed by Stockmeier [139]. Deliberate self-harm patients had a significantly reduced 5-HT$_{2A}$ frontal binding index. The reduction was more pronounced among self-injury patient than among self-poisoning patients [140]. In the recent study by Underwood and co-authors [141], the 5-HT$_{2A}$ binding was greater in the prefrontal cortex of MDD suicides with alcoholism and childhood adversity. Evidence from direct in vivo functional imaging with either PET or Single-Photon Emission Computed Tomography demonstrated contradicting results with lower [142–144], unchanged [145,146] and higher [147] levels of 5-HT$_{2A}$ binding in MDD patients.

Despite the huge amount of studies, the contribution of 5-HT$_{2A}$ polymorphisms to depressive disorders in humans is not fully understood. The number of meta-analyses did not show any significant association between polymorphisms in the Htr2a gene and depressive disorders [148–150]. However, recent gene-based analysis does suggest an association of the Htr2a gene with antidepressant treatment response in depressed patients [151,152].

The majority of studies devoted to finding a link between 5-HT$_{2A}$ receptor polymorphisms and suicidal risk failed to find any association [153–157]. At the same time, in a number of studies, an association between the Htr2a gene variants and suicidal behavior in subjects with stressful life events [158,159], such as sexual and physical child abuse, was found [160].

### 4.2. The 5-HT$_{2B}$ Receptor in Aggressive and Depressive Behavior

It has been generally assumed that 5-HT$_{2B}$ receptor dysfunction or deficiency resulted in increased impulsivity and aggression. High impulsivity was found in 5-HT$_{2B}$ mutant (Htr2b$^{-/-}$) mice [161]. Among the QTLs underlying behaviors associated with intermale aggression in mice, the strongest candidate within the narrow QTL interval on chromosome 1 for both attack and latency variables is Htr2b gene [162].

Humans with specific 5-HT$_{2B}$ receptor stop codon (Htr2b Q20*), that led to loss of receptor expression, are predisposed to severe impulsivity and aggressive behavior towards themselves and others [163–165]. Genomic-wide association studies and experiments on 5-HT knockout mice implicate the 5-HT$_{2B}$ receptor as a major locus associated with cannabis-induced aggression both in mice and humans [166].
A lack of SSRI effects was observed in $Htr2b^{-/-}$ [167] and $Htr2b^{5-\text{HTKO}}$ mice [112,168]. In contrast, agonist-induced stimulation of 5-HT$_{2B}$ receptors mimicked behavioral and neurogenic SSRI actions [167]. Of interest was that non-stressed 5-HT$_{2B}$ knockout mice displayed an antidepressant-like phenotype that was reversed to depressive-like after four weeks of social isolation [169]. There is much evidence that astroglial, rather than neuronal 5-HT$_{2B}$ receptor expression changes are associated with depressive behaviors [111]. Recently it was found that down-regulation of astrocytic 5-HT$_{2B}$ receptors may underlie depressive-like behavior induced by sleep deprivation, while restoration of receptor levels augments the antidepressant action [170]. Based on the existent literature data, we suggested a hypothetical mechanism of 5-HT$_{2B}$ receptors implicated in the mechanisms of depression (Figure 1).

**Figure 1.** Hypothetical mechanism of 5-HT$_{2B}$ receptors implicated in the mechanisms of depression. Under physiological conditions, 5-HT$_{2B}$ receptors directly modulate serotonergic neurotransmission as well as astrocytic functions; under stressful conditions, the 5-HT$_{2B}$ receptors are downregulated which may lead to both serotonergic and astrocytic dysfunctions.

### 4.3. The 5-HT$_{2C}$ Receptor

#### 4.3.1. The 5-HT$_{2C}$ Receptor in Aggressive Behavior

The role of 5-HT$_{2C}$ receptors in aggressive behavior has long remained elusive due to the lack of selective ligands [9]. To our knowledge, the first evidence of the implication of
5-HT<sub>2C</sub> receptors in aggressive behavior was obtained in our experiments on rats selected for many generations for high or low impulsive aggressiveness [171]. Significant difference between highly aggressive and nonaggressive rats in the expression and functional response of 5-HT<sub>2C</sub> receptors was shown. The level of 5-HT<sub>2C</sub> receptor mRNA in the frontal cortex and hippocampus and functional response to 5-HT<sub>2C</sub> receptor agonist was lower in aggressive rats than in nonaggressive animals, suggesting an inhibitory role of 5-HT<sub>2C</sub> receptors in genetically-defined aggressiveness.

There are a few currently available data in support of the antiaggressive role of 5-HT<sub>2C</sub> receptors: (1) the activation of 5-HT<sub>2C</sub> receptors enhanced the display of defeat submissive and defensive behavior in golden hamsters [172]. (2) 5-HT<sub>2C</sub> receptor agonist/alpha 2 receptor antagonist S32212 suppressed aggressive behavior in mice [173]. (3) Mice expressing only the VGV isoform of 5-HT<sub>2C</sub> receptors displayed a high level of conspecific aggression [174]. (4) The association between Htr2c gene polymorphism and criminal behavior in humans was demonstrated [175]. (5) Recently, a novel 5-HT<sub>2C</sub> agonist, lorcaserin, has been demonstrated to have antiaggressive properties in human subjects with impulsive aggressive behavior. Lorcaserin attenuated provoked, but not unprovoked, aggression in impulsively aggressive individuals indicating that 5-HT<sub>2C</sub> receptor may be a putative target for the treatment of impulsive aggressive behavior in human subjects [176].

4.3.2. 5-HT<sub>2C</sub> Receptor, Depressive Behavior and Suicide

Htr2c<sup>−/−</sup> mice do not exhibit depressive-like behavior in a TST paradigm [177]. However, 5-HT<sub>2C</sub> knockout enhanced fluoxetine effects on immobility in the TST [177]. Recently, Demireva and co-authors demonstrated that 5-HT<sub>2C</sub> receptor blockade led to augmentation of therapeutic antidepressant and anxiolytic effects of SSRIs [178]. Indeed, tricyclic antidepressants and SSRIs act as antagonists of 5-HT<sub>2C</sub> receptors, and when administered chronically, can lead to 5-HT<sub>2C</sub> receptor downregulation [179–183]. 5-HT<sub>2C</sub> receptor antagonists not only possess antidepressant and anxiolytic properties in diverse rodent models [184], but are also introduced as antidepressant drugs in clinics. One of them, agomelatine, has long been registered for the treatment of MDD [185]. On the other hand, 5-HT<sub>2C</sub> agonists also have antidepressant activity in various models of depressive-like behavior [186–188]. At least one of the explanations of paradoxical antidepressant-like effects of both agonists and antagonists of 5-HT<sub>2C</sub>, as well as 5-HT<sub>2A</sub> receptors, is an impact of the constitutive activity of these receptors [109,110]. Constitutive activity of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors is identified by receptor signaling in the absence of any ligand and it can change the response to drugs.

The role of 5-HT<sub>2C</sub> gene polymorphism in mood disorders has also been investigated. In many studies, an association between Ser23 allele of rs6318 SNP, MDD and BD as well as antidepressant response was found [189–193]. Postmortem analyses of 5-HT<sub>2C</sub> Receptor mRNA-editing profiles in the whole brain and hypothalamus [194], the prefrontal cortex [195–200] and the anterior cingulate cortex [201] in suicides with psychiatric disorders like MDD, schizophrenia and bipolar disorder consistently showed increased levels of these epigenetic modifications regardless of the underlying disease. Nevertheless, an association between Htr2c gene variants and suicidal behavior was not confirmed in the majority of studies [202–206].

The sum of data indicates the opposite roles of 5-HT<sub>2A/2C</sub> and 5-HT<sub>2B</sub> receptors in the regulation of affective behavior. The 5-HT<sub>2B</sub> receptors play an inhibitory role in both aggressive and depressive-like behavior, acting through direct modulation of serotonergic neurotransmission as well as astrocytic functions. Under stressful conditions, the 5-HT<sub>2B</sub> receptors are downregulated, in contrast to 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors that are upregulated and sensitized in response to stress. In turn, sensitized 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors indirectly inhibit serotonergic neurotransmission and provoke depressive-like behavior (Figure 2). At the same time, 5-HT<sub>2A/2C</sub> receptors play an opposite role in the regulation of impulsivity.
The sum of data indicates the opposite roles of 5-HT2A/2C and 5-HT2B receptors in the regulation of affective behavior. The 5-HT2B receptors play an inhibitory role in both aggressive and depressive-like behavior, acting through direct modulation of serotonergic neurotransmission as well as astrocytic functions. Under stressful conditions, the 5-HT2B receptors are downregulated, in contrast to 5-HT2A and 5-HT2C receptors that are upregulated and sensitized in response to stress. In turn, sensitized 5-HT2A and 5-HT2C receptors indirectly inhibit serotonergic neurotransmission and provoke depressive-like behavior.

Figure 2. Schematic representation of mechanisms of 5-HT2A and 5-HT2C receptor involvement in the pathogenesis of depression. Under physiological conditions, postsynaptic 5-HT2A and 5-HT2C receptors regulate glutamate and/or GABA release; upon stress-induced serotonin depletion, 5-HT2A and 5-HT2C receptors are upregulated and sensitized. Sensitized 5-HT2A and 5-HT2C receptors indirectly inhibit serotonergic neurotransmission, aggravate serotonin deficit and provoke depressive-like behavior.
5. The 5-HT\textsubscript{3} Receptor

The 5-HT\textsubscript{3} receptor is the only known exception among G-protein-coupled receptors in the 5-HT receptor family. Unlike all the others 5-HT receptors, the 5-HT\textsubscript{3} receptor is a ligand-gated ion channel. It belongs to the Cys-loop receptor family of pentametric neurotransmitter-gated ion channels permeable to Ca\textsuperscript{2+}, Na\textsuperscript{+} and K\textsuperscript{+}, and plays a key role in fast synaptic transmission. The 5-HT\textsubscript{3} receptor expressing neurons are mainly GABA cells in the neocortex, olfactory cortex, hippocampus and amygdala [207]. It was suggested that the activation of 5-HT\textsubscript{3} receptors inhibits pyramidal neurons in the medial prefrontal cortex via GABAergic interneurons [208]. In addition, 5-HT\textsubscript{3} receptors control dopamine and acetylcholine release, and this interrelation can be an important mechanism the 5-HT\textsubscript{3} receptor ligands effects [60].

The most well established physiological roles of the 5-HT\textsubscript{3} receptor are to regulate gastrointestinal motility and coordinate emesis and vomiting [60,209]. Thus, 5-HT\textsubscript{3} agonists cause unpleasant effects of nausea, vomiting and anxiety, and have not been used clinically owing to their emetogenic and anxiogenic properties [210]. Additionally, it was shown that central 5-HT\textsubscript{3} receptors play an important role in thermoregulation [211,212]. Meanwhile, 5-HT\textsubscript{3} antagonists produced distinct antiemetic activity for chemotherapy-induced vomiting and different kinds of chronic neuropathic nausea and vomiting [213]. Antagonists of 5-HT\textsubscript{3} receptors do not modify any aspects of normal behavior in animals or induce pronounced changes in physiological functions in healthy subjects [213]. The efficacy was shown mainly in pathological models of behavior [214]. Positive anti-inflammatory and immunomodulatory effects of 5-HT\textsubscript{3} antagonists (seemingly related to substance P-mediated inflammation and hyperalgesia) have also been observed [210].

5.1. The 5-HT\textsubscript{3} Receptor in Aggression

Antagonists of 5-HT\textsubscript{3} receptors—usually referred to as setrons (ondansetron, zacopride, tropisetron)—reduced alcohol-heightened aggression in mice [215], apomorphine-induced aggressive behavior in rats [216], and aggressive response of cocaine-treated hamsters, whereas 5-HT\textsubscript{3} receptor agonist mCPBG stimulated aggressive behavior in hamsters [217].

The 5-HT\textsubscript{3} receptor density was greater in highly aggressive (H-Agg) compared with low-aggressive (L-Agg) hamsters [218]. No significant effect of 5-HT\textsubscript{3} overexpression on aggressive behavior was found. However, ondansetron and zacopride reduced intermale aggression in both B6SJL/F2 transgenic 5-HT\textsubscript{3} overexpressing and wild-type mice [215].

These data showed the implication of the 5-HT\textsubscript{3} receptor in the regulation of aggressiveness and suggested the 5-HT\textsubscript{3} receptor as a pro-aggressive factor [218,219]. However, this suggestion met some controversies: (1) isolation-induced aggressive behavior is accompanied by down-regulated hypothalamic 5-HT\textsubscript{3} protein level. (2) Intrahypothalamic infusion of ondansetron increased isolation-induced aggression, whereas 5-HT\textsubscript{3} receptor agonist SR57227A decreased aggression levels [220]; and 5-HT\textsubscript{3} antagonist zacopride failed to attenuate isolation-induced aggression [122]. It therefore seems that the antiaggressive effect of the 5-HT\textsubscript{3} receptor antagonists is dependent upon the phenotype. Tropisetron inhibited expression of aggression in an impulsive-aggressive phenotype High-Aggression group of golden hamsters, while enhancing aggressive behavior in Low-Aggressive animals [219]. The aggression-reducing effect of 5-HT\textsubscript{3} receptor antagonists was found in the offensive response of adolescent cocaine-treated hamsters [217] and alcohol heightened aggression [215]. Taken together these data show 5-HT\textsubscript{3} receptor antagonists to be a promising antiaggression substance, although this effect depends on the genetic background of the animal and on the kind of aggression in question.
5.2. The 5-HT\textsubscript{3} Receptor in Depression

Accumulated evidence that is well covered in comprehensive reviews [60,214,221,222] suggested 5-HT\textsubscript{3} receptor antagonists as possible antidepressant drug targets. Indeed, 5-HT\textsubscript{3} receptor antagonists inhibit the binding of 5-HT to postsynaptic 5-HT\textsubscript{3} receptors and increase their availability to other receptors like 5-HT\textsubscript{1A}, 5-HT\textsubscript{1B} and 5-HT\textsubscript{2A} receptors, thereby producing an antidepressant effect [222]. Antidepressant-like effects of 5-HT\textsubscript{3} receptor antagonists ondansetron, zacopride, ICS 205-930 [181,223,224] and tropisetron [225] were demonstrated on mice and rats in various behavioral models of depression.

5.3. The 5-HT\textsubscript{3} Receptor in Suicidal Behavior

In contrast to numerous data demonstrating the link between the 5-HT\textsubscript{3} receptor, aggression and depression, investigations into the involvement of the 5-HT\textsubscript{3} receptor in suicidal behavior are scarce. The few currently available studies give a reason to believe that 5-HT\textsubscript{3} receptors are not involved in the predisposition to suicide. In particular, no differences in number and affinity of 5-HT\textsubscript{3} receptors in the cortex of suicide victims were shown [226]. The data concerning 5-HT\textsubscript{3A} and 5-HT\textsubscript{3B} receptor polymorphisms also suggest that 5-HT\textsubscript{3} receptors may not play a major role in the susceptibility to suicidal behavior in schizophrenia patients [227].

6. The 5-HT\textsubscript{7} Receptor

The 5-HT\textsubscript{7} receptor is one of the most recently described G-protein-coupled 5-HT receptors. This receptor exhibits a high percentage of homology with the 5-HT\textsubscript{1A} receptor and exerts its effects on neurons via the same second messenger as the 5-HT\textsubscript{1A} receptor—adenylyl cyclase. However, the 5-HT\textsubscript{7} receptor activates adenylyl cyclase, whereas the 5-HT\textsubscript{1A} receptor inhibits it.

6.1. The 5-HT\textsubscript{7} Receptor in Aggression

In contrast with very consistent lines of evidence that the 5-HT\textsubscript{7} receptor contributes to modulatory mechanisms of depression, efforts to evaluate the implication of the 5-HT\textsubscript{7} receptor in the control of aggressive behavior have been negative. To our knowledge, there are no studies establishing a link between the 5-HT\textsubscript{7} receptor and aggression. Administration of different doses of selective 5-HT\textsubscript{7} receptor antagonist SB269970 to mice did not produce any significant effect on isolation-induced aggressive behavior [228]. In our experiments (unpublished data), no effect on intermale aggression in mice was found of intracerebroventricularly administered 5-HT\textsubscript{7} receptor agonist, LP 44.

6.2. The 5-HT\textsubscript{7} Receptor in Depression

Studies utilizing 5-HT\textsubscript{7} antagonists demonstrated the involvement of 5-HT\textsubscript{7} receptors in the control of learning, circadian rhythmicity, sleep-disorders, mood and thermoregulation [229–232].

Converging lines of evidence suggested that 5-HT\textsubscript{7} receptors contribute to genetic and physiological control of depressive behavior: (1) various 5-HT\textsubscript{7} receptor antagonists including lurasidone [229,233], SB-269970 [234–236], SB-258719 [234], and JNJ-18038683 [237] produced antidepressant-like activity in the tail suspension and in the forced swimming tests; (2) 5-HT\textsubscript{7} receptor antagonism has been posited as necessary for antidepressant activity of antipsychotic amisulpride [238,239]; (3) 5-HT\textsubscript{7} knockout mice also showed decreased immobility in both Porsolt’s and tail suspension tests [234,235]; (4) chronic antidepressant treatment leads to decreased 5-HT\textsubscript{7} receptor binding [240].

Remarkable coincidence of the effects of antidepressant treatment, 5-HT\textsubscript{7} knockout and pharmacological blockade of 5-HT\textsubscript{7} receptors indicates that 5-HT\textsubscript{7} receptor facilitates the mechanisms provoking depression and suggest that 5-HT\textsubscript{7} antagonists might have therapeutic value as novel antidepressant drugs [235,241,242]. Moreover, a novel antipsychotic drug lurasidone which is notable for high affinity for 5-HT\textsubscript{7} receptor is approved for the treatment of schizophrenia and patients with major depressive episodes associ-
ated with bipolar depression in a number of countries including UK, USA, Canada and Australia [243].

Recently, a novel role of 5-HT_7 receptors in the functionality of the 5-HT system was revealed. The idea that G-protein-coupled receptors (GPCRs) can function as dimers is now generally accepted [244–246]. Moreover, a growing body of evidence points to the functional importance of oligomers for receptor trafficking, receptor activation and G-protein coupling in native tissues [246]. The clinical significance of GPCR oligomerization has also become more evident during recent years, leading to identification of oligomeric complexes as novel therapeutic targets [247,248].

Convincing evidence indicating that G-protein-coupled 5-HT receptors can interact with each other forming protein-protein complexes has been obtained. It was found that 5-HT_1A receptors form heterodimers with 5-HT_7 receptors (5-HT_1A-5-HT_7) [249,250]. Functionally, heterodimerization inhibits the binding of 5-HT_1A receptors to the Gi-protein, reducing the 5-HT_1A receptor-mediated potassium channel activation, and facilitates the internalization of 5-HT_1A receptors without affecting the 5-HT_7 receptor-mediated signaling [250]. Thus, the formation of the 5-HT_1A-5-HT_7 receptor complex enhances the desensitization of 5-HT_1A receptors with unchanged 5-HT_7 receptor functional activity. Although the evidence for the physiological significance of 5-HT_1A-5-HT_7 dimers has been obtained mainly from cell culture experiments, taking into account the acknowledged role of 5-HT_1A receptors in autoregulation of the brain 5-HT system, these data suggest 5-HT_7 receptors to be important regulators of 5-HT_1A activity.

The possible role of 5-HT_1A/5-HT_7 heterodimers in the development of pathophysiological processes in the central nervous system and in the effect of antidepressant treatment is of particular interest. We suggested that the higher sensitivity of presynaptic 5-HT_1A receptors to prolonged 5-HT stimulation compared to postsynaptic 5-HT_1A receptors is based on the larger density of 5-HT_1A/5-HT_7 heterodimers on the presynaptic membrane [251]. According to this hypothesis, the ratio of 5-HT_1A/5-HT_1A homodimers and 5-HT_1A/5-HT_7 heterodimers on pre- and postsynaptic terminals is not the same: 5-HT_1A/5-HT_7 heterodimeric complexes predominate on presynaptic terminals (Figure 3). SSRIs increase the level of 5-HT in the synaptic cleft, which enhances the internalization of 5-HT_1A/5-HT_7 receptor complexes. This leads to inhibition of the 5-HT_1A autoreceptor activity resulting in the increase in 5-HT system functional activity. Therefore, the formation of the 5-HT_1A/5-HT_7 heterodimeric complex may play a significant role both in the development of depression and in the mechanism of its treatment. We also suggested that under depression, the ratio of 5-HT_1A/5-HT_1A homo- to 5-HT_1A/5-HT_7 heterodimers in presynaptic neurons may shift towards 5-HT_1A/5-HT_1A homodimers, leading to a delay in 5-HT_1A autoreceptor internalization following SSRI treatment which could result in antidepressant resistance. If this hypothesis is correct, then artificial increase in 5-HT_7 receptor expression in the raphe nuclei area should lead to a shift in the ratios of 5-HT_1A/5-HT_1A homodimers and 5-HT_1A/5-HT_7 heterodimers towards 5-HT_1A/5-HT_7 heterodimers, enhance 5-HT_1A autoreceptor internalization and thus result in an antidepressant effect. Recently we verified this hypothesis, and showed that 5-HT_7 receptor overexpression in the raphe nuclei area of the midbrain of both “nondepressive” C57Bl/6j mice and ASC mice with genetic predisposition to depressive-like behavior produced an antidepressant effect [252].

Meanwhile, despite comprehensive evidence on the implication of the 5-HT_7 receptor in mood disturbances and MDD, there is no data on its role in the mechanisms underlying suicidal behavior.
Figure 3. Hypothetical mechanism of the role of 5-HT$_{1A}$/5-HT$_{7}$ receptor heterodimerization in the mechanism of depression. Under physiological conditions, the amount of 5-HT$_{1A}$/5-HT$_{7}$ heterodimers in presynaptic neurons is higher than in postsynaptic neurons; under depression, the 5-HT$_{1A}$/5-HT$_{1A}$ homo- and 5-HT$_{1A}$/5-HT$_{7}$ heterodimers ratio in presynaptic neurons shifts towards 5-HT$_{1A}$/5-HT$_{1A}$ homodimers which decreases the amount of 5-HT in the synaptic cleft.

7. Discussion

Deepening acquaintance with functional characteristics and the nature of the participation of individual 5-HT receptors in the regulation of pathological behavior is important not only for our understanding of the mechanisms regulating pathological aggressiveness, depression, and suicide, but also for creating new, more effective antidepressant and antiaggressive pharmacological medicines. Over the past decade, a number of attempts have been made to enhance antidepressant effects by combining drugs that increase serotonergic activity. The combined drug approach is based on the utilization of different pathways enhancing 5-HT signaling—increased 5-HT synthesis, inhibited 5-HT reuptake and catabolism, and increased receptor activity—as well as on the implementation of specific receptor agonists, or blockade with antagonists.

A successful example of this novel approach is the unique multimodal 5-HTergic drug vortioxetine, which combines a 5-HT reuptake inhibitor activity with agonistic 5-HT$_{1A}$ receptor activity and antagonistic 5-HT$_{3}$ and 5-HT$_{7}$ receptor activity. Preclinical and clinical trials have shown high efficacy of vortioxetine in MDD [253–255]. Vortioxetine was the first antidepressant to demonstrate clinical efficacy in improving cognition regardless of the effect on affective symptomatology [256,257]. Another advantage of vortioxetine over currently utilized antidepressants is a favorable effect in elderly patients [258]. Despite a large number of studies supporting vortioxetine, its place among antidepressants remains
unclear due to the insufficient number of studies devoted to comparison with currently used antidepressants, primarily with the drugs from the SSRI group [259].

The similar effect of SSRIs and some 5-HT receptors on depressive and aggressive behavior, i.e., suppressive effect of 5-HT1A receptors and facilitative 5-HT3 receptors (in absence of a significant effect of the 5-HT7 receptor on aggressiveness), suggests that vortioxetine should also have antiaggressive agent properties. Indeed, preliminary results support this assumption although so far obtained only for a very small number of patients [260].

Two main limitations of the multimodal drug approach are (1) potential danger of unwanted side-effects caused by increased action of a particular drug, e.g., hallucinogenic effects of 5-HT2A receptor activation, emesis and vomiting produced by activation of 5-HT3 receptors; (2) the danger of the Serotonin Syndrome (SS) development—toxic symptoms produced from too much 5-HT in the central and peripheral nervous system [261,262].

Nevertheless, the key role of 5-HT in the regulation of behavior and mechanisms underlying a wide range of neuro- and psychopathologies, on the one hand, and the poly-functionality and diversity of 5-HT receptors on the other hand, open broad prospects for the creation of new effective combined 5-HTergic drugs. As an example, an antidepressant drug litoxetine was developed, combining SERT inhibition and 5-HT3 antagonism to prevent SSRI-induced gastrointestinal side effects [263]. However, our growing knowledge of the role of 5-HT also highlights the necessity for a detailed investigation into the functional characteristics of all 5-HT receptor types as well as their cross-talk and roles in the regulation of numerous types of behavior.

8. Conclusions

Aggression, depression, and suicide are multifactorial behavioral conditions controlled by an ensemble of 5-HT receptor types exerting reciprocal suppressive or facilitative influence.

Currently, the brain 5-HT system is the main target for antidepressant drugs: almost all clinically effective antidepressants act via 5-HTergic neurons (the only exception being bupropion) [23]. Available 5-HT receptor density data suggest that the antidepressant effect of SSRIs is only observable when inhibitory and excitatory 5-HT receptors are balanced [25].

This review examines the evidence for the contribution of seven types of 5-HT receptors to the regulation of aggressive, depressive and suicidal behavior in an attempt to identify similarities and differences in the 5-HT receptor ensemble underlying these psychopathologies.

Comparison of aggressive and depressive behavior reveals significant similarities in the 5-HT receptors set and in the character of their modulating effect suggesting that impulsive violent aggressive behavior and depression share common genetic and epigenetic mechanisms. Along with 5-HT1A, 5-HT1B, and 5-HT2B receptors, the activation of which produces antidepressant effects and suppresses (decreases) aggressiveness, 5-HT3 receptor agonists enhance both aggressiveness and depressive-like behavior (Table 1). The differences might be found in the effect of 5-HT7 receptor agonists, which enhance depression and, apparently, do not play a significant role in the regulation of aggressive behavior.

Paradoxically, an antidepressant effect may be produced by both agonists and antagonists of 5-HT1B, 5-HT2A and 5-HT2C receptors (Table 1), suggesting posttranslational modification due to the regional differences. Additionally, for these receptor subtypes, biased agonism was demonstrated. This phenomenon results in activation of different signal pathways depending on the ligand [24,264–266]. At the same time, for 5-HT2C receptors, mRNA-editing resulting in the translation of various isoforms of receptor was shown [267–269]. These features could also explain the paradoxically antidepressant effect induced by both agonist and antagonist of these receptors. Moreover, this rather disappointing situation of combined effects may be associated with the constitutive features of these types of 5-HT receptors, which are active even in the absence of a ligand. This may determine the unusual response of 5-HT2A/2C receptors to antagonists [270].
Table 1. Summarized effects of 5-HT receptors on aggression and depression. Activating effect is shown by up arrow; suppressing effect is shown by down arrow; bidirectional effect is shown by double arrow; no effect is shown by straight line.

| Receptor | Aggression | Depression |
|----------|------------|------------|
| 5-HT1A   | ↓          | ↑          |
| 5-HT1B   | ↓          | ↓          |
| 5-HT2A   | ↑          | ↑          |
| 5-HT2B   | ↓          | ↓          |
| 5-HT2C   | ↓          | ↑          |
| 5-HT3    | ↑          | ↑          |
| 5-HT7    |            |            |

The investigation of the individual roles of different 5-HT receptors in the mechanisms underlying suicide is complicated—not only by the great diversity of suicidal behavior (suicide ideation, suicidal attempt, completed suicide, depressive or violent suicide), but also, most importantly, by the lack of experimental animal model of suicide [72]. Nevertheless, the available data indicate the involvement of at least some of the 5-HT receptors in the mechanisms of suicide. This applies in particular to the main autoregulator of the brain 5-HT system—the 5-HT1A receptor. An increase in the 5-HT1A autoreceptor density in the raphe nuclei area of individuals who attempted suicide [66,73] and who committed suicide [74] was found. Indeed, 5-HT1A receptors in the raphe nuclei act as somatodendritic autoreceptors, and an increase in their activity leads to a decrease in 5-HT signaling in the brain that is in good agreement with the prevailing ideas about the role of 5-HT deficiency in psychopathologies. No changes in 5-HT1A receptor density in the prefrontal cortex of suicide victims were revealed [74]. However, a decrease in activity of cortical 5-HT1A receptor downstream effectors in suicide victims was shown [77]. Recently, the association of suicide with the disruption of cortical 5-HT1A receptor functioning in MDD patients was demonstrated [78]. Another 5-HT receptor likely to be involved in mechanisms underlying suicide is the 5-HT2A receptor. The 5-HT2A receptor level in the frontal cortex is reported to be increased in suicide victims [21,141] but the 5-HT2A receptor binding index in the frontal cortex of deliberate self-harm patients was decreased. An explanation of this discrepancy can be found in the study of Andenaert with co-authors [142], who showed that the nature of changes in 5-HT2A receptors closely depends on the type of suicide—depressive or violent.

Author Contributions: Conceptualization, N.K.P.; writing—original draft preparation, N.K.P., A.S.T. and V.S.N.; writing—review and editing, N.K.P., A.S.T. and V.S.N.; project administration and funding acquisition, V.S.N. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Russian Science Foundation, grant No. 22-15-00011.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations

5-HT  Serotonin
SSRI  serotonin-selective reuptake inhibitor
MDD  Major Depressive Disorder
GPCR  G-protein coupled receptor
PET  positron emission tomography
siRNA  small interfering RNA
7-TMS  7-transmembrane-spanning receptors
cyclic GMP  cyclic guanosine monophosphate
BPD  borderline personality disorder
QTLs  Quantitative Trait Loci
TST  Tail Suspension Test
SNP  single nucleotide polymorphism
BD  bipolar affective disorder
ASC  antidepressant sensitive cataleptics
SS  Serotonin Syndrome
SERT  serotonin transporter

References

1. Souery, D.; Oswald, P.; Linkowski, P.; Mendlewicz, J. Molecular genetics in the analysis of suicide. *Ann. Med.* 2003, 35, 191–196. [CrossRef] [PubMed]
2. Knipe, D.; Padmanathan, P.; Newton-Howes, G.; Chan, L.F.; Kapur, N. Suicide and self-harm. *Lancet* 2022, 399, 1903–1916. [CrossRef]
3. Amidfar, M.; Kim, Y.K. Recent Developments on Future Antidepressant-related Serotonin Receptors. *Curr. Pharm. Des.* 2018, 24, 2541–2548. [CrossRef]
4. Siever, L.J. Neurobiology of aggression and violence. *Am. J. Psychiatry* 2008, 165, 429–442. [CrossRef] [PubMed]
5. Linnoila, V.M.; Virkkunen, M. Aggression, suicidality, and serotonin. *J. Clin. Psychiatry* 1992, 53, 46–51. [PubMed]
6. Pfeffer, C.R.; Jiang, H.; Kakuma, T. Child-Adolescent Suicidal Potential Index (CASPI): A screen for risk for early onset suicidal behavior. *Psychol. Assess.* 2000, 12, 304–318. [CrossRef] [PubMed]
7. Conner, K.R.; Cox, C.; Duberstein, P.R.; Tian, L.; Nisbet, P.A.; Conwell, Y. Violence, alcohol, and completed suicide: A case-control study. *Am. J. Psychiatry* 2001, 158, 1701–1705. [CrossRef]
8. Conner, K.R.; Swogger, M.T.; Houston, R.J. A test of the reactive aggression-suicidal behavior hypothesis: Is there a case for proactive aggression? *J. Abnorm. Psychol.* 2009, 118, 235–240. [CrossRef]
9. Bortolato, M.; Pivac, N.; Muck Seler, D.; Nikolac Perkovic, M.; Pessia, M.; Di Giovanni, G. The role of the serotonergic system at the interface of aggression and suicide. *Neuroscience* 2013, 236, 160–185. [CrossRef]
10. Plutchik, R. Outward and inward directed aggressiveness: The interaction between violence and suicidality. *Pharmacopsychiatry* 1995, 28 (Suppl. S2), 47–57. [CrossRef]
11. West, D.J. *Murder Followed by Suicide*; Heinemann: London, UK, 1965.
12. Gregory, M.J.; Milroy, C.M. Homicide and suicide in Yorkshire and the Humber: 1975–1992 and 1993–2007. *Am. J. Forensic Med. Pathol.* 2010, 31, 58–63. [CrossRef] [PubMed]
13. Van Praag, H.M. (Auto)aggression and CSF 5-HIAA in depression and schizophrenia. *Psychopharmacol. Bull.* 1995, 31, 58–63. [CrossRef] [PubMed]
14. Jans, L.A.; Riedel, W.J.; Markus, C.R.; Blokland, A. Serotonergic vulnerability and depression: Assumptions, experimental evidence and implications. *Mol. Psychiatry* 2007, 12, 522–543. [CrossRef]
15. Kaufman, J.; Sullivan, G.M.; Yang, J.; Ogden, R.T.; Miller, J.M.; Oquendo, M.A.; Mann, J.J.; Parsey, R.V.; DeLorenzo, C. Quantification of the Serotonin 1A Receptor Using PET: Identification of a Potential Biomarker of Major Depression in Males. *Neuropsychopharmacology* 2015, 40, 1692–1699. [CrossRef]
16. Popova, N.K. From genes to aggressive behavior: The role of serotonergic system. *Bioessays* 2006, 28, 495–503. [CrossRef]
17. Takahashi, A.; Quadros, I.M.; de Almeida, R.M.; Miczek, K.A. Behavioral and pharmacogenetics of aggressive behavior. *Curr. Top. Behav. Neurosci.* 2012, 12, 73–138. [CrossRef]
18. Hakulinen, C.; Jokela, M.; Hintsanen, M.; Merjonen, P.; Pulkki-Raback, L.; Seppala, I.; Lyytikainen, L.P.; Lehtimaki, T.; Kahonen, M.; Viikari, J.; et al. Serotonin receptor 1B genotype and hostility, anger and aggressive behavior through the lifespan: The Young Finns study. *J. Behav. Med.* 2013, 36, 583–590. [CrossRef]
19. Bellivier, F.; Szoke, A.; Henry, C.; Lacoste, J.; Bottos, C.; Nosten-Bertrand, M.; Hardy, P.; Rouillon, F.; Launay, J.M.; Laplanche, J.L.; et al. Possible association between serotonin transporter gene polymorphism and violent suicidal behavior in mood disorders. *Biol. Psychiatry* 2000, 48, 319–322. [CrossRef]
20. Mann, J.J.; Malone, K.M.; Sweeney, J.A.; Brown, R.P.; Linnoila, M.; Stanley, B.; Stanley, M. Attempted suicide characteristics and cerebrospinal fluid amine metabolites in depressed inpatients. *Neuropsychopharmacology* 1996, 15, 576–586. [CrossRef]
47. Cleare, A.J.; Bond, A.J. Ipirsonone challenge in aggressive men shows an inverse correlation between 5-HT1A receptor function and aggression. *Psychopharmacology* 2000, 148, 344–349. [CrossRef] [PubMed]
48. Lai, M.K.; Tsang, S.W.; Francis, P.T.; Esiri, M.M.; Keene, J.; Hope, T.; Chen, C.P. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. *Brain Res.* 2003, 974, 82–87. [CrossRef]
49. Jiang, Y.F.; Liu, J.; Yang, J.; Guo, Y.; Hu, W.; Zhang, J.; La, X.M.; Xie, W.; Wang, H.S.; Zhang, L. Involvement of the Dorsal Hippocampus 5-HT1A Receptors in the Regulation of Depressive-Like Behaviors in Hemiparkinsonian Rats. *Neuropsychobiology* 2020, 79, 198–207. [CrossRef]
50. Hui, Y.P.; Zhang, Q.J.; Zhang, L.; Chen, L.; Guo, Y.; Qiao, H.F.; Wang, Y.; Liu, J. Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson’s disease. *Neuroscience* 2014, 268, 265–275. [CrossRef]
51. Zhou, J.; Cao, X.; Mar, A.C.; Ding, Y.Q.; Wang, X.; Li, Q.; Li, L. Activation of postsynaptic 5-HT1A receptors improve stress adaptation. *Psychopharmacology* 2014, 231, 2067–2075. [CrossRef]
52. Carr, G.V.; Lucki, I. The role of serotonin receptor subtypes in treating depression: A review of animal studies. *Psychopharmacology* 2011, 213, 265–287. [CrossRef]
53. Albert, P.R.; Vahid-Ansari, F. The 5-HT1A receptor: Signaling to behavior. *Biochimie* 2013, 161, 34–45. [CrossRef] [PubMed]
54. Richardson-Jones, J.W.; Craige, C.P.; Guilard, B.P.; Stephen, A.; Metzger, K.L.; Kung, H.F.; Gardier, A.M.; Dranovsky, A.; David, D.J.; Beck, S.G.; et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. *Neuron* 2010, 65, 40–52. [CrossRef] [PubMed]
55. Bortolozzi, A.; Castane, A.; Semakova, J.; Santana, N.; Alvarado, G.; Cortes, R.; Ferres-Coy, A.; Fernandez, G.; Carmona, M.C.; Toth, M.; et al. Selective sRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. *Mol. Psychiatry* 2012, 17, 612–623. [CrossRef] [PubMed]
56. Bortolozzi, A.; Castane, A.; Semakova, J.; Santana, N.; Alvarado, G.; Cortes, R.; Ferres-Coy, A.; Fernandez, G.; Carmona, M.C.; Toth, M.; et al. New antidepressant strategy based on acute siRNA silencing of 5-HT1A autoreceptors. *Mol. Psychiatry* 2012, 17, 567. [CrossRef] [PubMed]
57. Ferres-Coy, A.; Santana, N.; Castane, A.; Cortes, R.; Carmona, M.C.; Toth, M.; Montefeltro, A.; Artigas, F.; Bortolozzi, A. Acute 5-HT(1A) autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions. *Psychopharmacology* 2013, 225, 61–74. [CrossRef]
58. De Paulis, T. Drug evaluation: Vilazodone—A combined SSRI and 5-HT1A partial agonist for the treatment of depression. *IDrugs* 2007, 10, 193–201.
59. Celada, P.; Puig, M.; Amargos-Bosch, M.; Adell, A.; Artigas, F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. *J. Psychiatry Neurosci.* 2004, 29, 252–265.
60. Artigas, F. Serotonin receptors involved in antidepressant effects. *Pharmacol. Ther.* 2013, 137, 119–131. [CrossRef]
61. Vahid-Ansari, F.; Daigle, M.; Manzini, M.C.; Tanaka, K.F.; Hen, R.; Geddes, S.D.; Beique, J.C.; James, J.; Merali, Z.; Albert, P.R. Abrogated Freud-1/Cc2d1a Repression of 5-HT1A Autoreceptors Induces Fluoxetine-Resistant Anxiety/Depression-Like Behavior. *J. Neurosci.* 2017, 37, 11967–11978. [CrossRef]
62. Kondaurova, E.M.; Rodnyy, A.Y.; Ichibaeva, T.V.; Tsybko, A.S.; Eremin, D.V.; Antonov, Y.V.; Popova, N.K.; Naumenko, V.S. Genetic Background Underlying 5-HT1A Receptor Functioning Affects the Response to Fluoxetine. *Int. J. Mol. Sci.* 2020, 21, 8784. [CrossRef]
63. Turcotte-Cardin, V.; Vahid-Ansari, F.; Luckhart, C.; Daigle, M.; Geddes, S.D.; Tanaka, K.F.; Hen, R.; James, J.; Merali, Z.; Beique, J.C.; et al. Loss of Adult 5-HT1A Autoreceptors Results in a Paradoxical Anxiogenic Response to Antidepressant Treatment. *J. Neurosci.* 2019, 39, 1334–1346. [CrossRef] [PubMed]
64. Kondaurova, E.M.; Plyuschina, A.V.; Ichibaeva, T.V.; Eremin, D.V.; Rodnyy, A.Y.; Grygoreva, Y.D.; Naumenko, V.S. Effects of a Cc2d1a/Freud-1 Knockdown in the Hippocampus on Behavior, the Serotonin System, and BDNF. *Int. J. Mol. Sci.* 2021, 22, 13319. [CrossRef] [PubMed]
65. Albert, P.R.; Le Francois, B.; Vahid-Ansari, F. Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: The 5-HT1A receptor gene as a paradigm. *J. Psychiatry Neurosci.* 2019, 44, 164–176. [CrossRef] [PubMed]
66. Stockmeier, C.A.; Shapiro, L.A.; Dilley, G.E.; Kolli, T.N.; Friedman, L.; Rajkowska, G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. *J. Neurosci.* 1998, 18, 7394–7401. [CrossRef]
67. Lopez-Figueroa, A.L.; Norton, C.S.; Lopez-Figueroa, M.O.; Armellini-Dodel, D.; Burke, S.; Akil, H.; Lopez, J.F.; Watson, S.J. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. * Biol. Psychiatry* 2004, 55, 225–233. [CrossRef]
68. Drevets, W.C.; Frank, E.; Price, J.C.; Kuperf, D.J.; Holt, D.; Greer, P.J.; Huang, Y.; Gautier, C.; Mathis, C. PET imaging of serotonin 1A receptor binding in depression. *Biol. Psychiatry* 1999, 46, 1375–1387. [CrossRef]
69. Sargent, P.A.; Kjaer, K.H.; Bench, C.J.; Rabiner, E.A.; Messa, C.; Meyer, J.; Gunn, R.N.; Grasby, P.M.; Coven, P.J. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-106635: Effects of depression and antidepressant treatment. *Arch. Gen. Psychiatry* 2000, 57, 174–180. [CrossRef]
70. Neumeister, A.; Young, T.; Stastny, J. Implications of genetic research on the role of the serotonin in depression: Emphasis on the serotonin type 1A receptor and the serotonin transporter. *Psychopharmacology* 2004, 174, 512–524. [CrossRef]
71. Wang, L.; Zhou, C.; Zhu, D.; Wang, X.; Fang, L.; Zhong, J.; Mao, Q.; Sun, L.; Gong, X.; Xia, J.; et al. Serotonin-1A receptor alterations in depression: A meta-analysis of molecular imaging studies. *BMC Psychiatry* 2016, 16, 319. [CrossRef]

72. Malkesman, O.; Fine, D.S.; Tragon, T.; Austin, D.R.; Henter, I.D.; Chen, G.; Manji, H.K. Animal models of suicide-trait-related behaviors. *Trends Pharmacol. Sci.* 2009, 30, 165–173. [CrossRef]

73. Oquendo, M.A.; Galfalvy, H.; Sullivan, G.M.; Miller, J.M.; Milak, M.M.; Sublette, M.E.; Cisneros-Trujillo, S.; Burke, A.K.; Parsey, R.V.; Mann, J.J. Positron Emission Tomographic Imaging of the Serotonergic System and Prediction of Risk and Lethality of Future Suicidal Behavior. *JAMA Psychiatry* 2016, 73, 1048–1055. [CrossRef] [PubMed]

74. Sullivan, G.M.; Oquendo, M.A.; Milak, M.; Miller, J.M.; Burke, A.; Ogden, R.T.; Parsey, R.V.; Mann, J.J. Positron emission tomography quantification of serotonin(1A) receptor binding in suicide attempters with major depressive disorder. *JAMA Psychiatry* 2015, 72, 169–178. [CrossRef]

75. Boldrini, M.; Underwood, M.D.; Mann, J.J.; Arango, V. Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. *J. Psychiatr. Res.* 2008, 42, 433–442. [CrossRef] [PubMed]

76. Savitz, J.; Lucki, I.; Drevets, W.C. 5-HT(1B) receptor function in major depressive disorder. *Neuroscience* 2015, 272, 533–554. [CrossRef]

77. Faccidomo, S.; Quadros, I.M.; Takahashi, A.; Fish, E.W.; Miczek, K.A. Escalated aggression after alcohol drinking in male mice: Dorsal raphe and prefrontal cortex serotonin and 5-HT(1B) receptors. *Neuropsychopharmacology* 2008, 33, 525–605. [CrossRef]

78. Centenaro, L.A.; Vieira, K.; Zimmermann, N.; Miczek, K.A.; Lucion, A.B.; de Almeida, R.M. Social instigation and aggressive behavior in mice: Role of 5-HT1A and 5-HT1B receptors in the prefrontal cortex. *Neuropsychopharmacology* 2008, 201, 237–248. [CrossRef]

79. Ruf, B.M.; Bhagwagar, Z. The 5-HT1B receptor: A novel target for the pathophysiology of depression. *Curr. Drug Targets* 2009, 10, 1118–1138. [CrossRef]

80. Tiger, M.; Varnas, K.; Okubo, Y.; Lundberg, J. The 5-HT1B receptor—A potential target for antidepressant treatment. *Psychopharmacology* 2018, 235, 1317–1334. [CrossRef]

81. Sari, Y. Serotonin1B receptors: From protein to physiological function and behavior. *Neurosci. Biobehav. Rev.* 2004, 28, 565–582. [CrossRef]

82. Nakahata, T.; et al. Attenuated palmitoylation of serotonin receptor 5-HT1A affects receptor function and contributes to depression-like behaviors. *Nat. Commun.* 2019, 10, 3924. [CrossRef]

83. Faccidomo, S.; Bannai, M.; Miczek, K.A. 5-HT(1B) receptor inhibition of alcohol-heightened aggression in male mice: Comparison to drinking and running. *Neuropsychopharmacology* 2008, 201, 460–474. [CrossRef] [PubMed]

84. Malkesman, O.; Pine, D.S.; Tragon, T.; Austin, D.R.; Henter, I.D.; Chen, G.; Manji, H.K. Animal models of suicide-trait-related behaviors. *Trends Pharmacol. Sci.* 2009, 30, 165–173. [CrossRef]
96. Murrough, J.W.; Henry, S.; Hu, J.; Gallezot, J.D.; Planeta-Wilson, B.; Neumaier, J.F.; Neumeister, A. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. *Psychopharmacology* 2011, 213, 547–553. [CrossRef] [PubMed]

97. Evrard, A.; Laporte, A.M.; Chastanet, M.; Hen, R.; Hamon, M.; Adrien, J. 5-HT1A and 5-HT1B receptors control the firing of serotonergic neurons in the dorsal raphe nucleus of the mouse: Studies in 5-HT1B knock-out mice. *Eur. J. Neurosci.* 1999, 11, 3823–3831. [CrossRef] [PubMed]

98. Nishiguchi, N.; Shirakawa, O.; Ono, H.; Nishimura, A.; Nushida, H.; Ueno, Y.; Maeda, K. No evidence of an association between 5HT1B receptor gene polymorphism and suicide victims in a Japanese population. *Am. J. Med. Genet.* 2001, 105, 343–345. [CrossRef]

99. Hong, C.J.; Pan, G.M.; Tsai, S.J. Association study of onset age, attempted suicide, aggressive behavior, and schizophrenia with a serotonin 1B receptor (A-161T) genetic polymorphism. *Neuropsychobiology* 2004, 49, 1–4. [CrossRef]

100. Rujescu, D.; Giegling, I.; Sato, T.; Moller, H.J. Lack of association between serotonin 5-HT1B receptor gene polymorphism and suicidal behavior. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* 2003, 116B, 69–71. [CrossRef]

101. Stefu, J.; Buttnre, A.; Skavic, J.; Zill, P.; Balija, M.; Eisenmenger, W.; Bondy, B.; Jernej, B. Serotonin 1B (5-HT-1B) receptor polymorphism (G861C) in suicide victims: Association studies in German and Slavic population. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* 2004, 127B, 48–50. [CrossRef]

102. Tsai, S.J.; Hong, C.J.; Yu, Y.W.; Chen, T.J.; Wang, Y.C.; Lin, W.K. Association study of serotonin 1B receptor (A-161T) genetic polymorphism and suicidal behaviors and response to fluoxetine in major depressive disorder. *Neuropsychobiology* 2004, 50, 235–238. [CrossRef]

103. Videtic, A.; Pungercic, G.; Pajnic, I.Z.; Zupanc, T.; Balazic, J.; Tomori, M.; Komel, R. Association study of seven polymorphisms in four serotonin receptor genes on suicide victims. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* 2006, 141B, 669–672. [CrossRef] [PubMed]

104. Kao, W.T.; Yang, M.C.; Lung, F.W. Association between HTR1B alleles and suicidal ideation in individuals with major depressive disorder. *Neurosci. Lett.* 2017, 638, 204–210. [CrossRef] [PubMed]

105. Hannon, J.; Hoyer, D. Molecular biology of 5-HT receptors. *Mol. Cells* 2004, 17, 296–320. [CrossRef] [PubMed]

106. Hall, H.; Farde, L.; Halldin, C.; Lundkvist, C.; Sedvall, G. Autoradiographic localization of 5-HT(2A) receptors in the human brain using [3H](MK10907 and [(11)C]MK10907. *Synapse* 2000, 38, 421–431. [CrossRef]

107. Varnas, K.; Halldin, C.; Hall, H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. *Hum. Brain Mapp.* 2004, 22, 246–260. [CrossRef] [PubMed]

108. Beique, J.C.; Campbell, B.; Perring, P.; Hamblin, M.W.; Walker, P.; Mladenovic, L.; Andrade, R. Serotonergic regulation of membrane potential in developing rat prefrontal cortex: Coordinated expression of 5-hydroxytryptamine (5-HT)1A, 5-HT2A, and 5-HT7 receptors. *J. Neurosci.* 2004, 24, 4807–4817. [CrossRef]

109. Berg, K.A.; Harvey, J.A.; Spampinato, U.; Clarke, W.P. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression. *Prog. Brain Res.* 2008, 172, 287–305. [CrossRef]

110. Aloyo, V.J.; Berg, K.A.; Spampinato, U.; Clarke, W.P.; Harvey, J.A. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. *Pharmacol. Ther.* 2009, 121, 160–173. [CrossRef]

111. Peng, L.; Song, D.; Li, B.; Verkhratsky, A. Astroglial 5-HT2B receptor in mood disorders. *Expert Rev. Neurother.* 2018, 18, 435–442. [CrossRef]

112. Quentin, E.; Belmer, A.; Maroteaux, L. Somato-Dendritic Regulation of Raphe Serotonin Neurons; A Key to Antidepressant Action. *Frontot. Neurosci.* 2018, 12, 982. [CrossRef]

113. Bockaert, J.; Claeysen, S.; Becamel, C.; Dumuis, A.; Marin, P. Neuronal 5-HT metabotropic receptors: Fine-tuning of their structure, signaling, and roles in synaptic modulation. *Cell Tissue Res.* 2006, 326, 553–572. [CrossRef] [PubMed]

114. Nichols, D.E.; Nichols, C.D. Serotonin receptor polymorphism. *Chem. Rev.* 2008, 108, 1614–1641. [CrossRef]

115. Saxena, P.R.; De Vries, P.; Villalon, C.M. 5-HT1-like receptors: A time to bid goodbye. *Front. Neurosci.* 2012, 6, 8–13. [CrossRef]

116. Chagraoui, A.; Thibault, F.; Skiba, M.; Thuiliez, C.; Bourin, M. 5-HT2C receptors in psychiatric disorders: A review. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 2018, 66, 120–135. [CrossRef]

117. Alex, K.D.; Pehek, E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. *Pharmacol. Ther.* 2007, 113, 296–320. [CrossRef]

118. Chagraoui, A.; Thibault, F.; Skiba, M.; Thuiliez, C.; Bourin, M. 5-HT2C receptors in psychiatric disorders: A review. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 2016, 66, 120–135. [CrossRef]

119. Sakaue, M.; Aso, Y.; Sowa, C.; Sakamoto, Y.; Nishihara, B.; Koyama, Y.; Baba, A.; Matsuda, T. Modulation by 5-hT2A receptors of aggressive behavior in isolated mice. *Jpn. J. Pharmacol.* 2002, 89, 89–92. [CrossRef]

120. Juarez, P.; Valdovinos, M.G.; May, M.E.; Lloyd, B.P.; Couppis, M.H.; Kennedy, C.H. Serotonin(2)A/C receptors mediate the aggressive phenotype of TLX gene knockout mice. *Behav. Brain Res.* 2013, 256, 354–361. [CrossRef]

121. Godar, S.C.; Mosher, L.J.; Scheggi, S.; Devoto, P.; Moench, K.M.; Strathman, H.J.; Jones, C.M.; Frau, R.; Melis, M.; Gambarana, C.; et al. Gene-environment interactions in antisocial behavior are mediated by early-life 5-HT2A receptor activation. *Neuropsychopharmacology* 2019, 159, 10751. [CrossRef]
122. White, S.M.; Kucharik, R.F.; Moyer, J.A. Effects of serotonergic agents on isolation-induced aggression. Pharmacol. Biochem. Behav. 1991, 39, 729–736. [CrossRef]

123. Comai, S.; Tau, M.; Pavlovic, Z.; Gobbi, G. The psychopharmacology of aggressive behavior: A translational approach: Part 2. Clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J. Clin. Psychopharmacol. 2012, 32, 237–260. [CrossRef] [PubMed]

124. Butovskaya, M.L.; Butovskaya, P.R.; Vasilyev, V.A.; Sukhodolskaya, J.M.; Fekhredinova, D.I.; Karelin, D.V.; Fedenok, J.N.; Mabulla, A.Z.P.; Ryskov, A.P.; Lazeby, O.E. Serotonergic gene polymorphisms (5-HTTLPR, 5HTR1A, 5HTR2A), and population differences in aggression: Traditional (Hadza and Datoga) and industrial (Russians) populations compared. J. Physiol. Anthropol. 2018, 37, 10. [CrossRef] [PubMed]

125. Banlaki, Z.; Elek, Z.; Nanasi, T.; Szekely, A.; Nemoda, Z.; Szekely, M.; Ronai, Z. Polymorphism in the serotonin receptor 2a (HTR2A) gene as possible predispositional factor for aggressive traits. PLoS ONE 2015, 10, e0117792. [CrossRef] [PubMed]

126. Nomura, M.; Kusumi, I.; Kaneko, M.; Masui, T.; Daiguji, M.; Ueno, T.; Koyama, T.; Nomura, Y. Involvement of a polymorphism in the 5-HT2A receptor gene in impulsive behavior. Psychopharmacology 2006, 187, 30–35. [CrossRef] [PubMed]

127. Rylands, A.J.; Hinz, R.; Jones, M.; Holmes, S.E.; Feldmann, M.; Brown, G.; McMahon, A.W.; Talbot, P.S. Pre- and postsympaptic serotonergic differences in males with extreme levels of impulsive aggression without callous unemotional traits: A positron emission tomography study using (11)C-DASB and (11)C-MDL100907. Biol. Psychiatry 2012, 72, 1004–1011. [CrossRef]

128. Da Cunha-Bang, S.; Stenbaek, D.S.; Holst, K.; Licht, C.L.; Jensen, P.S.; Frokjaer, V.G.; Mortensen, E.L.; Knudsen, G.M. Trait aggression and trait impulsivity are not related to frontal cortex 5-HT2A receptor binding in healthy individuals. Psychiatry Res. 2013, 212, 125–131. [CrossRef]

129. Soloff, P.H.; Price, J.C.; Meltzer, C.C.; Fabio, A.; Frank, G.K.; Kaye, W.H. 5HT2A receptor binding is increased in borderline personality disorder. Biol. Psychiatry 2007, 62, 580–587. [CrossRef]

130. Soloff, P.H.; Chiappetta, L.; Mason, N.S.; Becker, C.; Price, J.C. Effects of serotonin-2A receptor binding and gender on personality traits and suicidal behavior in borderline personality disorder. Psychiatry Res. 2014, 222, 140–148. [CrossRef]

131. Rosell, D.R.; Thompson, J.L.; Stifflstein, M.; Xu, X.; Frankle, W.G.; New, A.S.; Goodman, M.; Weinstein, S.R.; Laruelle, M.; Abid-Dargham, A.; et al. Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol. Psychiatry 2010, 67, 1154–1162. [CrossRef]

132. Oquendo, M.A.; Russo, S.A.; Underwood, M.D.; Kassir, S.A.; Ellis, S.P.; Mann, J.J.; Arango, V. Higher postmortem prefrontal 5-HT2A receptor binding correlates with lifetime aggression in suicide. Biol. Psychiatry 2006, 59, 235–243. [CrossRef]

133. Knudsen, G.M. Sustained effects of single doses of classical psychedelics in humans. Neuropsychopharmacology 2022. [CrossRef] [PubMed]

134. Weissstau, N.V.; Zhou, M.; Lira, A.; Lambe, E.; Gonzalez-Maeso, J.; Hornung, J.P.; Sibille, E.; Underwood, M.; Itohara, S.; Dauer, W.T.; et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006, 313, 536–540. [CrossRef] [PubMed]

135. Petit, A.C.; Quesseveur, G.; Gressier, F.; Collé, R.; David, D.J.; Gardier, A.M.; Ferreri, F.; Lepine, J.P.; Falissard, B.; Verstuyft, C.; et al. Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 54, 76–82. [CrossRef] [PubMed]

136. Mestre, T.A.; Zurovski, M.; Fox, S.H. 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders. Expert. Opin. Investig. Drugs 2013, 22, 411–421. [CrossRef]

137. Marek, G.J.; Martin-Ruiz, R.; Abo, A.; Artigas, F. The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 2005, 30, 2205–2215. [CrossRef] [PubMed]

138. Hamon, M.; Blier, P. Monoamine neurotranscircuitry in depression and strategies for new treatments. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 45, 54–63. [CrossRef] [PubMed]

139. Stockmeier, C.A. Involvement of serotonin in depression: Evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J. Psychiatr. Res. 2003, 37, 357–373. [CrossRef]

140. Audenaert, K.; Van Laere, K.; Dumont, F.; Slegers, G.; Mertens, J.; van Heeringen, C.; Dierckx, R.A. Decreased frontal serotonin 5-HT 2a receptor binding index in deliberate self-harm patients. Eur. J. Nucl. Med. 2001, 28, 175–182. [CrossRef]

141. Underwood, M.D.; Kassir, S.A.; Bakalian, M.J.; Galfalvy, H.; Dworak, A.J.; Mann, J.J.; Arango, V. Serotonin receptors and suicide, major depression, alcohol use disorder and reported early life adversity. Transl. Psychiatry 2018, 8, 279. [CrossRef]

142. Audenaert, K.; Peremans, K.; Goethals, I.; van Heeringen, C. Functional imaging, serotonin and the suicidal brain. Acta Neurol. Belg. 2006, 106, 125–131.

143. Messa, C.; Colombo, C.; Moresco, R.M.; Gobbo, C.; Galli, L.; Lucignani, G.; Gilardi, M.C.; Rizzo, G.; Smeraldi, E.; Zanardi, R.; et al. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: A PET study. Psychopharmacology 2003, 167, 72–78. [CrossRef] [PubMed]

144. Biver, F.; Wikler, D.; Lotstra, F.; Damhaut, P.; Goldman, S.; Mendlewicz, J. Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex. Br. J. Psychiatry 1999, 171, 444–448. [CrossRef] [PubMed]

145. Meltzer, C.C.; Price, J.C.; Mathis, C.A.; Greer, P.J.; Cantwell, M.N.; Houck, P.R.; Mulans, B.H.; Ben-Eliezer, D.; Lopresti, B.; DeKosky, S.T.; et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am. J. Psychiatry 1999, 156, 1871–1878. [CrossRef] [PubMed]
160. Brezo, J.; Bureau, A.; Merette, C.; Jomphe, V.; Barker, E.D.; Vitaro, F.; Hebert, M.; Carbonneau, R.; Tremblay, R.E.; Turecki, G.; Ben-Efraim, Y.J.; Wasserman, D.; Wasserman, J.; Sokolowski, M. Family-based study of HTR2A in suicide attempts: Observed risk of schizophrenia but not bipolar disorder or major depressive disorder: A meta-analysis. *J. Neurosci. Res.* 2013, 91, 623–633.

161. Pitychoutis, P.M.; Belmer, A.; Moutkine, I.; Adrien, J.; Maroteaux, L. Mice Lacking the Serotonin Htr2B Receptor Gene Present an Antipsychotic-Sensitive Schizophrenic-Like Phenotype. *Neuropsychopharmacology* 2015, 40, 2764–2773. [CrossRef] [PubMed]

162. Delprato, A.; Bonheur, B.; Algeo, M.P.; Dhawan, E.; Lu, L.; Williams, R.W.; Crusio, W.E. A quantitative trait locus on chromosome 1 modulates intrameal aggression in mice. *Genes Brain Behav.* 2018, 17, e12469. [CrossRef]

163. Tikkanen, R.; Tiihonen, J.; Rautiainen, M.R.; Paunio, T.; Bevilacqua, L.; Panarsky, R.; Goldman, D. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis. *J. Affect. Disord.* 2013, 150, 649–652. [CrossRef] [PubMed]

164. Bevilacqua, L.; Goldman, D. Genetics of impulsive behaviour. *Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.* 2013, 368, 20120380. [CrossRef] [PubMed]
169. Diaz, S.L.; Narboux-Neme, N.; Boutourlinsky, K.; Doly, S.; Maroteaux, L. Mice lacking the serotonin 5-HT2B receptor as an animal model of resistance to selective serotonin reuptake inhibitors antidepressants. *Eur. Neuropsychopharmacol.* 2016, 26, 265–279. [CrossRef]

170. Li, X.; Liang, S.; Li, Z.; Li, S.; Xia, M.; Verkrhatsky, A.; Li, B. Leptin Increases Expression of 5-HT2B Receptors in Astrocytes Thus Enhancing Action of Fluoxetine on the Depressive Behavior Induced by Sleep Deprivation. *Front. Psychiatry* 2018, 9, 734. [CrossRef]

171. Popova, N.K.; Naumenko, V.S.; Kozhemyakina, R.V.; Plyusnina, I.Z. Functional characteristics of serotonin 5-HT2A and 5-HT2C receptors in the brain and the expression of the 5-HT2A and 5-HT2C receptor genes in aggressive and non-aggressive rats. *Neurosci. Behav. Physiol.* 2010, 40, 357–361. [CrossRef]

172. Harvey, M.L.; Swallows, C.L.; Cooper, M.A. A double dissociation in the effects of 5-HT2A and 5-HT2C receptors on the acquisition and expression of conditioned defeat in Syrian hamsters. *Behav. Neurosci.* 2012, 126, 530–537. [CrossRef]

173. Dekeyne, A.; Brocco, M.; Loiseau, F.; Gobert, A.; Verkhratsky, A.; Fone, K.C.; Watson, D.J.; et al. S2212, a novel serotonin type 2C receptor inverse agonist/alpha2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization. *J. Pharmacol. Exp. Ther.* 2012, 340, 765–780. [CrossRef] [PubMed]

174. Martin, C.B.; Ramond, F.; Farrington, D.T.; Aguiar, A.S., Jr.; Chevarin, C.; Berthiau, A.S.; Herrick-Davis, K.; Hamon, M.; et al. RNA splicing and editing modulation of 5-HT(2C) receptor function: Relevance to anxiety and aggression in VGV mice. *Mol. Psychiatry* 2013, 18, 656–665. [CrossRef]

175. Toshchakova, V.A.; Bakhtiari, Y.; Kulikov, A.V.; Gusev, S.I.; Trofinova, M.V.; Fedorenko, O.Y.; Mikhailitskaya, E.V.; Popova, N.K.; Bokhan, N.A.; Hovens, J.E.; et al. Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders. *Neuropsychobiology* 2017, 75, 200–210. [CrossRef] [PubMed]

176. Coccaro, E.F.; Lee, R.J. 5-HT2c agonist, lorcaserin, reduces aggressive responding in intermittent explosive disorder: A pilot study. *Hum. Psychopharmacol.* 2019, 34, e2714. [CrossRef] [PubMed]

177. Cremers, T.I.; Giorgetti, M.; Bosker, F.J.; Hogg, S.; Arnt, J.; Mork, A.; Honig, G.; Bogeso, K.P.; Westerink, B.H.; den Boer, H.; et al. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade. *Neuropsychopharmacology* 2004, 29, 1782–1789. [CrossRef] [PubMed]

178. Demireva, E.Y.; Suri, D.; Morelli, E.; Mahadevia, D.; Chuhma, N.; Teixeira, C.M.; Ziolkowski, A.; Hersh, M.; Fifer, J.; Bagchi, S.; et al. 5-HT2C receptor blockade reverses SSRI-associated basal ganglia dysfunction and potentiates therapeutic efficacy. *Mol. Psychiatry* 2020, 25, 3304–3321. [CrossRef] [PubMed]

179. Millan, M.J. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies. *Therapeutic* 2005, 60, 441–460. [CrossRef]

180. Martin, J.R.; Bos, M.; Jenck, F.; Moreau, J.; Mutel, V.; Sleight, A.J.; Wichmann, J.; Andrews, J.S.; Berendsen, H.H.; Broekkamp, C.L.; et al. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. *Psychopharmacology* 2008, 199, 549–568. [CrossRef] [PubMed]

181. Palivimaki, E.P.; Roth, B.L.; Majasuo, H.; Laakso, A.; Kuoppamaki, M.; Syvalhti, E.; Hietala, J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. *Psychopharmacology* 1996, 126, 234–240. [CrossRef] [PubMed]

182. Redrobe, J.P.; Bourin, M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. *Eur. J. Pharmacol.* 1997, 325, 129–135. [CrossRef]

183. Ni, Y.G.; Miledi, R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). *Proc. Natl. Acad. Sci. USA* 1997, 94, 2036–2040. [CrossRef] [PubMed]

184. Rosenzweig-Lipson, S.; Sabb, A.; Stack, G.; Mitchell, P.; Lucki, I.; Malberg, J.E.; Grauer, S.; Brennan, J.; Cryan, J.F.; Sukoff Rizzo, S.J.; et al. Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. *Psychopharmacology* 2004, 170, 330–331. [CrossRef] [PubMed]

185. Palivos, T.; Vaylonis, C.; Venero, R.; Doring, J.; Tartaglia, L.; Klameter, E.; et al. Association of Polymorphic Variants of 5HT2A and 5HT2C Genes with Antidepressant Therapy of Patients with a Current Depressive Episode. *Zhurnal Nevrol. Psikhiatrii Im. SS Korsakova* 2017, 117, 58–61. [CrossRef]

186. Martin, J.R.; Bos, M.; Jenck, F.; Moreau, J.; Mutel, V.; Sleight, A.J.; Wichmann, J.; Andrews, J.S.; Berendsen, H.H.; Broekkamp, C.L.; et al. 5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential. *J. Pharmacol. Exp. Ther.* 1998, 286, 913–924. [CrossRef] [PubMed]

187. Vyalova, N.M.; Pozhidaev, I.V.; Osmanova, D.Z.; Simutkin, G.G.; Ivanova Scapital, A.C.; Bokhan, N.A. Association of polymorphic variants of 5HT5A2A and 5HT2C genes with response to antidepressant therapy of patients with a current depressive episode. *Zhurnal Nevrol. Psikhiatrii Im. SS Korsakova* 2017, 117, 58–61. [CrossRef] [PubMed]

188. Tang, W.K.; Tang, N.; Liao, C.D.; Liang, H.J.; Mok, V.C.; Ungvari, G.S.; Wong, K.S. Serotonin receptor 2C gene polymorphism associated with post-stroke depression in Chinese patients. *Genet. Mol. Res.* 2013, 12, 1546–1553. [CrossRef] [PubMed]
212. Voronova, I.P.; Naumenko, V.S.; Khramova, G.M.; Kozyreva, T.V.; Popova, N.K. Central 5-HT3 receptor-induced hypothermia is associated with reduced metabolic rate and increased heat loss. Eur. J. Pharmacol. 2009, 653–659. [CrossRef] [PubMed]

213. Farber, L.; Haus, U.; Spath, M.; Drechsler, S. Physiology and pathophysiology of the 5-HT3 receptor. Neuropharmacology 2008, 4801–4813. [CrossRef] [PubMed]

214. Fitzgerald, L.W.; Iyer, G.; Conklin, D.S.; Krause, C.M.; Marshall, A.; Patterson, J.P.; Tran, D.P.; Jonak, G.J.; Hartig, P.R. Messenger RNA editing of the human serotonin 5-HT2C receptor. Neuropsychopharmacology 1999, 21, 825–905. [CrossRef]

215. McKenzie-Quirk, S.D.; Girasa, K.A.; Allan, A.M.; Miczek, K.A. 5-HT(3) receptors, alcohol and aggressive behavior in mice. Behav. Pharmacol. 2005, 16, 163–169. [CrossRef] [PubMed]
216. Rudissaar, R.; Pruus, K.; Skrebuhhova, T.; Allikmets, L.; Matto, V. Modulatory role of 5-HT3 receptors in mediation of apomorphine-induced aggressive behaviour in male rats. Behav. Brain Res. 1999, 106, 91–96. [CrossRef]

217. Ricci, L.A.; Knyshhevski, I.; Melloni, R.H., Jr. Serotonin type 3 receptors stimulate offensive aggression in Syrian hamsters. Behav. Brain Res. 2005, 156, 19–29. [CrossRef] [PubMed]

218. Cervantes, M.C.; Delville, Y. Serotonin 5-HT1A and 5-HT3 receptors in an impulsive-aggressive phenotype. Behav. Neurosci. 2009, 123, 589–598. [CrossRef] [PubMed]

219. Cervantes, M.C.; Biggs, E.A.; Delville, Y. Differential responses to serotonin receptor ligands in an impulsive-aggressive phenotype. Behav. Neurosci. 2010, 124, 435–469. [CrossRef]

220. Shimizu, K.; Kurosawa, N.; Seki, K. The role of the AMPA receptor and 5-HT(3) receptor on aggressive behavior and depressive-like symptoms in chronic social isolation-reared mice. Physiol. Behav. 2016, 153, 70–83. [CrossRef]

221. Juza, R.; Vlcek, P.; Mezeiova, E.; Musilek, K.; Soukup, O.; Korabecny, J. Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders. Med. Res. Rev. 2020, 40, 1593–1678. [CrossRef]

222. Bhatt, S.; Devadoss, T.; Manjula, S.N.; Rajangam, J. 5-HT3 receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders. Curr. Neuropharmacol. 2021, 19, 1545–1559. [CrossRef]

223. Mitchell, E.A.; Pratt, J.A. Neuroanatomical structures involved in the action of the 5-HT3 antagonist ondansetron: A 2-deoxyglucose autoradiographic study in the rat. Brain Res. 1991, 538, 289–294. [CrossRef]

224. Martin, P.; Gozlan, H.; Puech, A.J. 5-HT3 receptor antagonists reverse helpless behaviour in rats. Eur. J. Pharmacol. 1992, 212, 73–78. [CrossRef]

225. Bravo, G.; Maswood, S. Acute treatment with 5-HT3 receptor antagonist, tropisetron, reduces immobility in intact female rats exposed to the forced swim test. Pharmacol. Biochem. Behav. 2006, 85, 362–368. [CrossRef] [PubMed]

226. Mann, J.J.; Arango, V.; Henteleff, R.A.; Lagattuta, T.F.; Wong, D.T. Serotonin 5-HT3 receptor binding kinetics in the cortex of suicide victims are normal. J. Neural. Neurosci. 1996, 103, 165–171. [CrossRef] [PubMed]

227. Souza, R.P.; De Luca, V.; Manchia, M.; Kennedy, J.L. Are serotonin 3A and 3B receptor genes associated with suicidal behavior in schizophrenia subjects? Neurosci. Lett. 2011, 489, 137–141. [CrossRef] [PubMed]

228. Navarro, J.F.; Ibanez, M.; Luna, G. Behavioral profile of SB 269970, a selective 5-HT(7) serotonin receptor antagonist, in social encounters between male mice. Methods Find. Exp. Clin. Pharmacol. 2004, 26, 515–518. [CrossRef] [PubMed]

229. Thomas, D.R.; Hagan, J.J. 5-HT7 receptors. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 81–90. [CrossRef]

230. Naumenko, V.S.; Kondaurova, E.M.; Popova, N.K. On the role of brain 5-HT7 receptor in the mechanism of hypothermia: Comparison with hypothermia mediated via 5-HT1A and 5-HT3 receptor. Neuropharmacology 2011, 61, 1360–1365. [CrossRef]

231. Romano, E.; Ruocco, L.A.; Nativo, P.; Lacivita, E.; Ajmone-Cat, M.A.; Boatto, G.; Nieddu, M.; Tino, A.; Sadile, A.G.; Minghetti, L.; et al. Modulatory effects following subchronic stimulation of brain 5-HT7-R in mice and rats. Rev. Neurosci. 2014, 25, 383–400. [CrossRef]

232. Monti, J.M.; Jantos, H. The role of serotonin 5-HT7 receptor in regulating sleep and wakefulness. Rev. Neurosci. 2014, 25, 429–437. [CrossRef]

233. Cates, L.N.; Roberts, A.J.; Huitron-Resendiz, S.; Hedlund, P.B. Effects of lurasidone in behavioral models of depression. Role of the 5-HT(7) receptor subtype. Neuropharmacology 2013, 70, 211–217. [CrossRef] [PubMed]

234. Guscott, M.; Bristow, L.J.; Hadingham, K.; Rosahl, T.W.; Beer, M.S.; Stanton, J.A.; Bromidge, F.; Owens, A.P.; Huscroft, I.; Myers, J.; et al. Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology 2005, 48, 492–502. [CrossRef] [PubMed]

235. Hedlund, P.B.; Huitron-Resendiz, S.; Henriksen, S.J.; Sutcliffe, J.G. 5-HT7 receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern. Biol. Psychiatry 2005, 58, 831–837. [CrossRef]

236. Bonaventure, P.; Dugovic, C.; Kramer, M.; De Boer, P.; Singh, J.; Wilson, S.; Bertelsen, K.; Di, J.; Shelton, J.; Aluisio, L.; et al. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in animal models of anxiety and depression. Neuropharmacology 2006, 51, 578–586. [CrossRef]

237. Abbas, A.I.; Hedlund, P.B.; Huang, X.P.; Tran, T.B.; Meltzer, H.Y.; Roth, B.L. Amisulpride is a potent 5-HT7 antagonist: Relevance for antidepressant actions in vivo. Psychopharmacology 2009, 205, 119–128. [CrossRef]

238. Nikiforuk, A.; Popik, P. Amisulpride promotes cognitive flexibility in rats: The role of 5-HT7 receptors. Behav. Brain Res. 2013, 248, 136–140. [CrossRef]

239. Hedlund, P.B.; Sutcliffe, J.G. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol. Sci. 2004, 25, 481–486. [CrossRef]

240. Loebel, A.; Citrome, L. Lurasidone: A novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych Bull. 2015, 39, 237–241. [CrossRef] [PubMed]
244. Devi, L.A. Heterodimerization of G-protein-coupled receptors: Pharmacology, signaling and trafficking. *Trends Pharmacol. Sci.* 2001, 22, 532–537. [CrossRef]

245. Bulenger, S.; Marullo, S.; Bouvier, M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. *Trends Pharmacol. Sci.* 2005, 26, 131–137. [CrossRef] [PubMed]

246. Rivero-Muller, A.; Chou, Y.Y.; Ji, I.; Lajic, S.; Hanyaloglu, A.C.; Jonas, K.; Rahman, N.; Ji, T.H.; Huhtaniemi, I. Rescue of defective G protein-coupled receptor function in vivo by intermolecular cooperation. *Proc. Natl. Acad. Sci. USA* 2010, 107, 2319–2324. [CrossRef]

247. Waldhoer, M.; Fong, J.; Jones, R.M.; Lunzer, M.M.; Sharma, S.K.; Kostenis, E.; Portoghese, P.S.; Whistler, J.L. A heterodimer-selective agonist shows in vivo relevance of G-protein-coupled receptor dimers. *Proc. Natl. Acad. Sci. USA* 2015, 102, 9050–9055. [CrossRef]

248. Gonzalez-Maeso, J.; Ang, R.L.; Yuen, T.; Chan, P.; Weissstaub, N.V.; Lopez-Gimenez, J.F.; Zhou, M.; Okaya, K.; Hallado, L.F.; Milligan, G.; et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. *Nature* 2008, 452, 93–97. [CrossRef]

249. Konaduova, E.M.; Bazovkina, D.V.; Naumenko, V.S. 5-HT1A/5-HT7 receptor interplay: Chronic activation of 5-HT7 receptors decreases the functional activity of 5-HT1A receptor and its content in the mouse brain. *Mol. Biol. 2017*, 51, 157–165. [CrossRef]

250. Renner, U.; Zeug, A.; Woehler, A.; Niebert, M.; Dityatev, A.; Dityateva, G.; Abdel-Galil, D.; Frohlich, M.; et al. Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and trafficking. *J. Cell Sci.* 2012, 125, 2486–2499. [CrossRef]

251. Naumenko, V.S.; Popova, N.K.; Lacivita, E.; Leopoldo, M.; Ponimaskin, E.G. Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders. *CNS Neurosci. Ther.* 2014, 20, 582–590. [CrossRef]

252. Rodnyy, A.Y.; Konaduova, E.M.; Bazovkina, D.V.; Kulikova, E.A.; Ilchibavev, T.V.; Kovetskaya, A.I.; Baraboshkina, I.A.; Bazhenova, E.Y.; Popova, N.K.; Naumenko, V.S. Serotonin 5-HT7 receptor overexpression in the raphe nuclei area produces antidepressive effect and affects brain serotonin system in male mice. *J. Neurosci. Res.* 2022, 100, 1506–1523. [CrossRef]

253. Gonda, X.; Sharma, S.R.; Tarazi, F.I. Vortioxetine: A novel antidepressant for the treatment of major depressive disorder. *Expert Opin. Drug Discov.* 2019, 14, 81–89. [CrossRef] [PubMed]

254. Connolly, K.R.; Thase, M.E. Vortioxetine: A New Treatment for Major Depressive Disorder. *Expert Opin. Pharmacother.* 2016, 17, 421–431. [CrossRef] [PubMed]

255. Sanchez, C.; Assin, K.E.; Artigas, F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. *Pharmacol. Ther.* 2015, 145, 43–57. [CrossRef]

256. Dzivota, E.; Olajossy, M. Vortioxetine—The New Antidepressant Agent with Preclinical Properties. *Acta Pol. Pharm.* 2022, 77, 7–12. [CrossRef] [PubMed]

257. Al-Sukhni, M.; Maruschak, N.A.; McIntyre, R.S. Vortioxetine: A review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. *Expert Opin. Pharmacother.* 2021, 22, 1167–1177. [CrossRef] [PubMed]

258. Koesters, M.; Ostuzzi, G.; Guaiana, G.; Breilmann, J.; Barbui, C. Vortioxetine for depression in adults. *Cochrane Database Syst. Rev.* 2017, 7, CD011520. [CrossRef]

259. Marchiafava, M.; Piccirilli, M.; Bedetti, C.; Baglioni, A.; Menna, M.; Elisei, S. Effectiveness of serotonergic drugs in the management of problem behaviors in patients with neurodevelopmental disorders. *Psychiatr. Danub.* 2018, 30, 644–647. [CrossRef]

260. Talton, C.W. Serotonin Syndrome/Serotonin Toxicity. *Fed. Pract.* 2020, 37, 452–459. [CrossRef]

261. Insel, T.R.; Roy, B.F.; Cohen, R.M.; Murphy, D.I. Possible development of the serotonin syndrome in man. *Am. J. Psychiatry 1982*, 139, 954–955. [CrossRef]

262. Angel, I.; Schoemaker, H.; Prouteau, M.; Garreau, M.; Langer, S.Z. Litoxetine: A selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. *Eur. J. Pharmacol.* 1993, 232, 139–145. [CrossRef]

263. Jozwiak, K.; Plazinska, A. Structural Insights into Ligand-Receptor Interactions Involved in Biased Agonism of G-Protein Coupled Receptors. *Molecules 2021*, 26, 851. [CrossRef] [PubMed]

264. Muneta-Arrate, I.; Diez-Alarcia, R.; Horrillo, I.; Meana, J.J. Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Galphai- and neutral agonism for Galphai11-proteins in human brain cortex. *Eur. Neuropsychopharmacol.* 2020, 36, 83–89. [CrossRef] [PubMed]

265. Sniecikowska, J.; Gluch-Lutwin, M.; Bucki, A.; Wieckowska, A.; Siwak, A.; Jastrzebska-Wiesek, M.; Partyka, A.; Wilczynska, D.; Pytka, K.; Latacz, G.; et al. Discovery of Novel pERK1/2- or beta-Arrestin-Preferring 5-HT1A Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. *J. Med. Chem.* 2020, 63, 10946–10971. [CrossRef]

266. Berg, K.A.; Cropper, J.D.; Niswender, C.M.; Sanders-Bush, E.; Emsen, R.B.; Clarke, W.P. RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. *Br. J. Pharmacol.* 2001, 134, 386–392. [CrossRef]

267. Pauwels, P.J. Diverse signalling by 5-hydroxytryptamine (5-HT) receptors. *Biochem. Pharmacol.* 2000, 60, 1743–1750. [CrossRef]
269. Burns, C.M.; Chu, H.; Rueter, S.M.; Hutchinson, L.K.; Canton, H.; Sanders-Bush, E.; Emeson, R.B. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. *Nature* **1997**, *387*, 303–308. [CrossRef]

270. Berg, K.A.; Harvey, J.A.; Spampinato, U.; Clarke, W.P. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. *Trends Pharmacol. Sci.* **2005**, *26*, 625–630. [CrossRef]